var title_f3_51_3888="Hysterosc microinsert HSG";
var content_f3_51_3888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic sterilization microinsert: Post-procedure hysterosalpingogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Essure. Copyright &copy;2009 Conceptus, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3888=[""].join("\n");
var outline_f3_51_3888=null;
var title_f3_51_3889="Technetium Tc-99m tilmanocept: Drug information";
var content_f3_51_3889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m tilmanocept: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16338551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16338556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lymphoseek&reg;: FDA approved March 2013; anticipated availability is second quarter 2013.. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16338553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radiopharmaceutical diagnostic imaging agent indicated for lymphatic mapping with a handheld gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16338549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88729 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3889=[""].join("\n");
var outline_f3_51_3889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338551\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338556\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338553\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16338549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_51_3890="Mechanism of acromioclavicular joint injury";
var content_f3_51_3890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of acromioclavicular joint injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Injury to the acromioclavicular (AC) joint usually occurs from direct trauma to the superior or lateral aspect of the shoulder with the arm adducted, such as falling onto the shoulder. Greater force increases the risk of injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3890=[""].join("\n");
var outline_f3_51_3890=null;
var title_f3_51_3891="Stereotactic radiosurgery II";
var content_f3_51_3891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stereotactic radiosurgery for Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial section CT image through the sella turcica and pituitary gland of the patient shown in the previous figure. The magnification of the image is considerably greater; the anterior aspect of the image is at the top. The brown areas represent brain or other tissue; the black areas represent air-filled sinuses (eg, the space above and to the left of center is the sphenoid sinus, and the optic foramina are visible angling anterolaterally toward each upper corner of the image); the white areas represent bone (eg, the band below the pituitary gland, which has been artificially colored red and outlined in black, represent the posterior clinoid processes). A computer-assisted stereotactic \"photon knife\" treatment plan is superimposed on the CT image; it employs two isocenters of 15 Gy radiation delivered by a linear accelerator, one in each half of the anterior pituitary. Each concentric circle is an isorad 1 Gy less than the next inner circle. The cavernous sinuses will receive about 8 cGy of radiation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3891=[""].join("\n");
var outline_f3_51_3891=null;
var title_f3_51_3892="erythroderma d";
var content_f3_51_3892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroderma in the region of the ear in a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3892=[""].join("\n");
var outline_f3_51_3892=null;
var title_f3_51_3893="Hailey-Hailey 2";
var content_f3_51_3893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perianal Hailey-Hailey disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3893=[""].join("\n");
var outline_f3_51_3893=null;
var title_f3_51_3894="Melioidosis lung pathology";
var content_f3_51_3894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology of melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lung findings in a gross pathology specimen of melioidosis at autopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3894=[""].join("\n");
var outline_f3_51_3894=null;
var title_f3_51_3895="Aliskiren and hydrochlorothiazide: Drug information";
var content_f3_51_3895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aliskiren and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/32/12806?source=see_link\">",
"    see \"Aliskiren and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5661724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tekturna HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11574773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rasilez HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5661728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide;",
"     </li>",
"     <li>",
"      Renin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5662343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage must be individualized. Combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial therapy: Aliskiren 150 mg and hydrochlorothiazide 12.5 mg once daily, dose may be titrated at 2- to 4-week intervals; maximum recommended daily doses: Aliskiren 300 mg; hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add-on therapy: Initiate by adding the lowest available dose of the alternative component (aliskiren 150 mg or hydrochlorothiazide 12.5 mg); titrate to effect; maximum recommended daily doses: Aliskiren 300 mg; hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Replacement therapy: Substitute for the individually titrated components",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5662344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No initial dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5662345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: Initial: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: No dosage adjustment may be necessary (Vaidyanathan, 2007 [aliskiren]); however, risk of hyperkalemia and progressive renal dysfunction may occur with aliskiren; use with caution; hydrochlorothiazide is usually ineffective when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and is contraindicated in patients who are anuric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD (requiring hemodialysis): Initial: No dosage adjustment may be necessary (Khadzhynov, 2012 [aliskiren]); however, risk of hyperkalemia is increased with chronic aliskiren therapy; use with extreme caution; hydrochlorothiazide is usually ineffective when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and is contraindicated in patients who are anuric.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5662346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-severe: No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5662351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tekturna HCT&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     150/12.5: Aliskiren 150 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     150/25: Aliskiren 150 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     300/12.5: Aliskiren 300 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     300/25: Aliskiren 300 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5661726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6481543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time daily; may take with or without a meal, but consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5661730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, including use as initial therapy in patients likely to need multiple antihypertensives for adequate control",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5662327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies reported with combination product. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Renal: BUN increased (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (2%), vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (2%), uric acid level increased (2%), hyperkalemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1%), weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Hematocrit decreased, hemoglobin decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Angioedema, periorbital edema, and peripheral edema have been reported with aliskiren. Severe dermatologic reactions and pancreatitis have been reported with hydrochlorothiazide.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5661736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: Hypersensitivity to sulfonamide-derived drugs; anuria; concomitant use with an ACE inhibitor or ARB in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to aliskiren or any component of the formulation; history of angioedema with aliskiren, ACE inhibitors, or ARBs; hereditary or idiopathic angioedema; severe progressive renal disease and if increasing azotemia and oliguria occur during therapy; use in pregnant women; hyponatremia, hypercalcemia, symptomatic hyperuricemia, and conditions involving enhanced potassium loss; concomitant use with ACE-inhibitors or ARBs in patients with either type 2 diabetes mellitus or GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5661737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with renin inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Anaphylaxis and angioedema have been reported. Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with caution in any patient with a history of angioedema (of any etiology) as angioedema, some cases necessitating hospitalization and intubation, has been observed (rarely) with aliskiren use. Discontinue immediately following the occurrence of anaphylaxis or angioedema; do not readminister. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Early, aggressive, and appropriate management is critical. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: During the initiation of therapy, symptomatic hypotension may occur (rarely), particularly in volume- or salt-depleted patients. Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Due to the hydrochlorothiazide component photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control. Use of aliskiren (monotherapy or combined with ACE inhibitors or ARBs) in patients with type 2 diabetes mellitus has demonstrated an increased incidence of renal impairment, hypotension, and hyperkalemia; use is contraindicated in patients with diabetes mellitus who are taking an ACE inhibitor or ARB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment. Titrate slowly. Avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypovolemia: Avoid use or use a smaller dose in patients who are volume depleted; correct depletion prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution or avoid in patients with deteriorating renal function or low renal blood flow (eg, renal artery stenosis, severe heart failure); may increase risk of developing acute renal failure and hyperkalemia. Thiazide diuretics are not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute, loop diuretics are preferred over thiazides. Concomitant use of aliskiren with an ACE inhibitor or ARB may increase risk of developing acute renal failure and should be avoided in patients with GFR &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid concurrent use with strong inhibitors of P-glycoprotein (eg, cyclosporine, itraconazole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5662332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5662331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aliskiren may enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.  Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Aliskiren. Canagliflozin may enhance the hypotensive effect of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Aliskiren may decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Aliskiren. Management: Avoid concomitant use of aliskiren and grapefruit juice. Separation of aliskiren and grapefruit juice administration by several hours may reduce the chance for interaction. Monitor for decreased aliskiren levels/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11396050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5661731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5661732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5661734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5661735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5662348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; however, a high-fat meal reduces absorption. Consistent administration with regards to meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5988964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tekturna HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-12.5 mg (30): $118.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-25 mg (30): $118.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-12.5 mg (30): $149.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-25 mg (30): $149.89",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5662349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum electrolytes, BUN, serum creatinine; fluid status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Co-Rasilez (RU, TW);",
"     </li>",
"     <li>",
"      Rasilez D (AR, CN);",
"     </li>",
"     <li>",
"      Rasilez HCT (AT, AU, BE, BR, CH, CO, CZ, DE, DK, EC, EE, FR, GR, HK, ID, IE, IN, MY, NL, NO, PE, PH, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5662337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aliskiren is a direct renin inhibitor, resulting in blockade of the conversion of angiotensinogen to angiotensin I. Angiotensin I suppression decreases the formation of angiotensin II (Ang II), a potent blood pressure-elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention). Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5662339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Khadzhynov D, Slowinski T, Lieker I, et al, \"Pharmacokinetics of Aliskiren in Patients With End-Stage Renal Disease Undergoing Haemodialysis,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2012, 51(10):661-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/51/3895/abstract-text/23018529/pubmed\" id=\"23018529\" target=\"_blank\">",
"        23018529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaidyanathan S, Bigler H, Yeh C, et al, &ldquo;Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskerin Alone and in Combination with Irbesartan in Renal Impairment,&rdquo; Clin Pharmacokinet, 2007, 46(8):661-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/51/3895/abstract-text/17655373/pubmed\" id=\"17655373\" target=\"_blank\">",
"        17655373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villamil A, Chrysant SG, Calhoun D, et al, &ldquo;Renin Inhibition With Aliskiren Provides Additive Antihypertensive Efficacy When Used in Combination With Hydrochlorothiazide,&rdquo;",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 2007, 25(1):217-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/51/3895/abstract-text/17143194/pubmed\" id=\"17143194\" target=\"_blank\">",
"        17143194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9238 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3895=[""].join("\n");
var outline_f3_51_3895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708585\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661724\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11574773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661728\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662343\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662344\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662345\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662346\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662351\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661726\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6481543\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661730\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662327\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661736\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661737\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662332\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662331\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11396050\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661731\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661732\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661734\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5661735\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662348\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5988964\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662349\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961936\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662337\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5662339\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/32/12806?source=related_link\">",
"      Aliskiren and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_51_3896="Approaches to the therapeutic relationship in patients with personality disorders";
var content_f3_51_3896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approaches to the therapeutic relationship in patients with personality disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Andrew Skodol, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Donna Bender, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3896/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/51/3896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H89663711\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between a clinician and a patient in psychotherapy plays a central role in alleviating symptoms and fostering character change [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment relationship can be a potentially powerful vehicle for patient improvement, as it can provide a supportive environment for exploration and because issues that come up in this context can be processed in a very immediate and instructive way.",
"   </p>",
"   <p>",
"    Components of the therapeutic relationship, described and measured using the concept of a therapeutic or working alliance, facilitate patient and therapist engagement in a productive treatment endeavor. The alliance is one of the most robust predictors of outcome in psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20615?source=see_link&amp;anchor=H89663786#H89663786\">",
"     \"Establishing and maintaining a therapeutic relationship in psychiatric practice\", section on 'Therapeutic alliance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of establishing and maintaining a productive therapeutic relationship requires the clinician to consider the personality style and personality psychopathology of each individual patient. Personality fundamentally affects interpersonal relations, and personality pathology is always associated with significant interpersonal impairment in areas such as empathy and intimacy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic describes common treatment issues, problems, and opportunities in the clinician-patient therapeutic relationship. Approaches to the therapeutic relationship in patients with personality disorders are described separately. The epidemiology, clinical manifestations, diagnosis, and treatment of specific personality disorders are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20615?source=see_link\">",
"     \"Establishing and maintaining a therapeutic relationship in psychiatric practice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284827\">",
"    <span class=\"h1\">",
"     PERSONALITY DISORDERS AND TRAITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown that the quality of a patient&rsquo;s interpersonal relationships in general significantly affects the building and nature of the therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The clinician should consider an individual&rsquo;s characteristic way of relating, so that appropriate interventions (regardless of modality) can be made to effectively retain and involve the patient in the treatment. Forming a relationship with a patient is often difficult, however, particularly in work with patients with severely narcissistic, borderline, or paranoid personality characteristics, because troubled interpersonal attitudes and behaviors will affect the patient&rsquo;s engagement with the therapist.",
"   </p>",
"   <p>",
"    Diagnostic clusters of DSM-IV-TR personality disorders are useful in considering issues related to the therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/9\">",
"     9",
"    </a>",
"    ]. However, increasing evidence suggests that the DSM categories and clusters do not adequately capture the complexity of character pathology traits and symptoms. Patients often meet criteria for two or more personality disorders, perhaps spanning different clusters, such as the co-occurrence of schizotypal personality disorder with borderline personality disorder or borderline personality disorder with avoidant personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/10\">",
"     10",
"    </a>",
"    ], or a patient may not meet full criteria for any one disorder, but has prominent features associated with one or several personality disorders. Personality and personality pathology are often viewed dimensionally. Whether or not a patient meets full criteria for a specific DSM-IV-TR personality disorder, knowledge of his or her personality traits and patterns of personality functioning are critical for building and maintaining a therapeutic relationship.",
"   </p>",
"   <p>",
"    A clinician should determine which aspects of a patient&rsquo;s personality pathology are dominant at intake and should reassess the patient&rsquo;s personality status at various points over the course of treatment. The nature of the relationship established early in the treatment is most powerfully predictive of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/11\">",
"     11",
"    </a>",
"    ]. In a study of long-term psychotherapy with a group of borderline patients, for example, therapist ratings of the therapeutic alliance six weeks into treatment predicted subsequent dropouts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/12\">",
"     12",
"    </a>",
"    ]. A table (",
"    <a class=\"graphic graphic_table graphicRef83283 \" href=\"UTD.htm?5/50/5933\">",
"     table 1",
"    </a>",
"    ) summarizes tendencies of patients with each DSM-IV-TR personality disorder that may challenge early alliance-building, as well as aspects of the personality type through which a clinician might engage the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284852\">",
"    <span class=\"h2\">",
"     Cluster A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster A, the so-called odd-eccentric cluster, is comprised of schizotypal, schizoid, and paranoid personality disorders. Most relevant for building a therapeutic relationship is the profound impairment in the capacity to form interpersonal relationships associated with these disorders. Because of pronounced mistrust or interpersonal discomfort or withdrawal, people with characteristics of these personality disorders often do not seek treatment unless dealing with acute problems such as substance abuse. For those who do seek treatment, there is evidence that these patients have great difficulty establishing a therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284859\">",
"    <span class=\"h3\">",
"     Schizotypal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizotypal personalities often have one or no significant others outside family members; thus, it is often assumed that they have no desire to become involved in relationships. However, in many cases, these patients may be excruciatingly uncomfortable around people rather than lacking interest in social connection. Social discomfort may not be readily apparent; establishing a relationship with such patients may require being attentive to unspoken issues. The therapist may be a participant in some elaborate fantasy that makes it difficult for the patient to find some minimum level of comfort.",
"   </p>",
"   <p>",
"    A study assessed how 201 patients with different personality disorders reported thinking about their therapists, finding that patients with schizotypal personality disorder had the highest level of mental involvement with therapy outside the session [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/14\">",
"     14",
"    </a>",
"    ]. Schizotypal patients scored highly on factors about missing their therapists and wishing for friendship, while simultaneously feeling aggressive or negative toward them. Some members of the schizotypal group described longing fantasies of having the therapist as a romantic partner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284866\">",
"    <span class=\"h3\">",
"     Schizoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizoid personality is consistently associated with a lack of desire for intimate human connection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/15\">",
"     15",
"    </a>",
"    ]. Some people with a schizoid character can appear to live very conventional lives on the surface, eg, having families and jobs. However, they keep other people at an emotional distance. A pronounced lack of feelings of conflict, with associated affective coldness or dullness may be present, such that a schizoid person is unlikely to become anxious or depressed and, thus, often lacks motivation to seek treatment. Underlying the apparent detachment may be intense neediness for others and the capability to respond interpersonally to a few carefully selected people [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients who have more awareness of their interpersonal needs have a greater likelihood of forming a relationship in therapy, if they choose to seek treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284873\">",
"    <span class=\"h3\">",
"     Paranoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paranoid individuals are incessantly alert for threats and see threats where others do not, ie, they are vigilant for perceived slights, finding offense in even the most benign remarks or circumstances. Challenges to building a therapeutic relationship are pronounced, since a therapist will inevitably say or do something that provokes such an interpersonally sensitive patient. However, paranoid individuals are often defending an extremely fragile self-concept and may possibly be reached over time in treatment with an approach that includes unwavering affirmation and careful handling of the many possible ruptures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284880\">",
"    <span class=\"h2\">",
"     Cluster B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;dramatic&rdquo; cluster includes borderline, narcissistic, histrionic, and antisocial personality disorders. Each of these character styles is associated in some way with testing and pushing the limits of the treatment relationship, and great care is needed by clinicians to avoid crossing appropriate boundaries in a quest to build a relationship. Many Cluster B patients present the most daunting challenges to maintaining a therapeutic relationship. The tendency to engage with others in a sadomasochistic manner (eg, power struggles, provocative behavior, self-harm gestures) is common with Cluster B type pathology and poses particular perils for the treatment relationship. Strains and ruptures in the therapeutic relationship are quite common in patients with these disorders, and must be handled with skill, tact, and empathy. If negotiated effectively by the therapist, these challenges to treatment can serve to strengthen the relationship and deepen patients&rsquo; self-knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284887\">",
"    <span class=\"h3\">",
"     Borderline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The borderline person does not develop the ability to integrate the ubiquitous strengths and weakness of themselves and of others, but rather creates &ldquo;splits&rdquo; in his or her mind to protect good images from bad [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/18\">",
"     18",
"    </a>",
"    ]. Splitting leads to a poorly developed and integrated self-concept and identity problems. Building a therapeutic relationship can be difficult because patients frequently exhibit pronounced emotional upheaval, self-destructive acting-out, and views of the therapist that alternate between idealization and denigration. Within relationships, borderline individuals are very needy and demanding, often straining the boundaries of the treatment relationship and exerting pressure on clinicians to behave in ways they normally would not.",
"   </p>",
"   <p>",
"    Research has demonstrated that these pressures can impair the clinician&rsquo;s ability to reflect on his or her own mental states and those of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinicians who work with borderline patients must be able to tolerate and productively discuss anger and aggression directed at them. However, because borderline patients, in most cases, desperately seek interpersonal relationships, engagement in treatment is often possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a treatment study of borderline patients employing psychodynamic psychotherapy, a strong alliance and good treatment outcome were linked to two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A solid commitment by the therapist to remain engaged in the treatment until the patient has made significant gains",
"     </li>",
"     <li>",
"      Special emphasis on facilitating the patients&rsquo; expression of aggression and rage without fear of retaliation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies of the treatment of patients with borderline personality disorder have demonstrated the importance of the therapist vigilantly attending to the alliance and to the repair of moment-to-moment disruptions in the alliance in order to maintain the viability of the psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284894\">",
"    <span class=\"h3\">",
"     Narcissistic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narcissistic individuals have a fundamental deficit in the ability to regulate self-esteem without resorting to strategies of overcompensation or over-reliance on admiration by others [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/22\">",
"     22",
"    </a>",
"    ]. Narcissistically vulnerable individuals have difficulty maintaining a cohesive sense of self because of overwhelming shame, resulting from a sense that they fundamentally fall short of an internal ideal self. These patients may have hidden compensation strategies reflected in a private sense of entitlement to being seen as special. Constant reinforcement from others is sought to bolster fragile self-images. When this internal dynamic manifests as excessive self-effacement and social reticence, it is referred to alternatively as vulnerable, deflated, or covert narcissism.",
"   </p>",
"   <p>",
"    Alternatively, people who are behaving in obviously grandiose and entitled ways (those who might meet criteria for DSM-IV-TR narcissistic personality disorder) are said to exhibit grandiose or overt narcissism. Greater emphasis may be placed on attempting to maintain self-esteem through omnipotent fantasies and by defeating others. Personal belief centers on the notion that he or she is perfect, and so love and admiration will be received from other &ldquo;ideal people,&rdquo; and there is no need to associate with inferiors. In its most extreme form, this manifestation of character pathology is referred to as malignant narcissism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Narcissistic personality traits pose significant challenges in building a therapeutic relationship. The patient will need to not allow the therapist to voice anything that represents an alternative view to that of the patient&rsquo;s. For narcissistic patients, other people, including the therapist, do not exist as separate individuals, but merely to gratify their needs. The clinician must tolerate this degree of vulnerability and self-protection, sometimes for a lengthy period of time before trust develops [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284901\">",
"    <span class=\"h3\">",
"     Histrionic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a histrionic personality needs to be the center of attention and may behave in seductive ways in an attempt to keep the clinician entertained and engaged. Emotional expression is often shallow or greatly exaggerated. The histrionic patient, however, assumes a deep connection has been made with the therapist and dependence can develop very quickly. He or she has very little tolerance for frustration, resulting in demands for immediate gratification. Attention-seeking attributes can be helpful in establishing a preliminary therapeutic relationship. However, as with patients with borderline pathology, the clinician must be prepared to manage escalating demands and dramatic acting-out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284908\">",
"    <span class=\"h3\">",
"     Antisocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisocial personality is associated with ongoing violation of society&rsquo;s norms, manifested in such behaviors as theft, intimidation, violence, or making a living in an illegal fashion (eg, by fraud or selling drugs). People with antisocial personality disorder have little or no regard for the welfare of others. This personality disorder is found extensively among inmates within the prison system.",
"   </p>",
"   <p>",
"    Gradations in the severity of the antisocial style are associated with different treatment outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/25\">",
"     25",
"    </a>",
"    ]. Milder forms are more amenable to treatment; however, patients at the more severe end of the antisocial spectrum are not generally successful in treatment. These individuals are sadistic and manipulative, pathological liars, show no empathy, compassion, or remorse for hurting others, and take no responsibility for their actions. Those who are additionally violent are the most difficult to engage in treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empirical evidence shows that some antisocial patients are capable of forming a treatment alliance resulting in positive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/26\">",
"     26",
"    </a>",
"    ]. However, there is a risk of developing a &ldquo;pseudoalliance&rdquo; with an antisocial patient. The patient may act as if a relationship existed to gain certain advantages, particularly within an institutional context (eg, in a hospital or prison) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/27\">",
"     27",
"    </a>",
"    ]. Individuals may profess disingenuously to have increased their self-understanding and pretend to move toward reform as an attempt to manipulate the therapist into recommending inappropriate dispensations or privileges. Therapists who work with these types of individuals must maintain vigilance, self-reflection and a healthy skepticism so as not to be charmed or misled into thinking the patient has suddenly and miraculously changed, or into agreeing to inappropriate arrangements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284915\">",
"    <span class=\"h3\">",
"     Sadomasochistic character",
"    </span>",
"    &nbsp;&mdash;&nbsp;While sadomasochism is not a distinct personality disorder in DSM-IV-TR, sadomasochistic tendencies are most dramatically overt in patients with borderline, narcissistic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antisocial personalities, although this pattern can be found across the spectrum of personality disorder pathology. Sadomasochistic interpersonal patterns are characteristic ways of engaging others in a struggle in which one party is suffering at the hands of the other. Patients with a sadomasochistic approach to relationships often subtly sabotage treatment in an attempt to punish the therapist.",
"   </p>",
"   <p>",
"    A patient may seem at times to agree with a therapist&rsquo;s observations, but actually experiences them as verbal assaults, while masochistically suffering in silence and showing no improvement in treatment. Behavior may be highly provocative, attempting to &ldquo;bait&rdquo; the therapist into saying negative things. Acting out in apparently punishing ways may be common, such as attempting suicide using a newly prescribed medication when it seemed as though the treatment was progressing.",
"   </p>",
"   <p>",
"    Trauma in the form of a loss of a parent, loss of love as a result of abuse or neglect, or the experience of loss of the self due a severe childhood illness, may underlie sadomasochistic tendencies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/28\">",
"     28",
"    </a>",
"    ]. From this perspective, the cruel behavior of the sadist may be an attempt to punish the other person (in this case, a therapist) for threatened abandonment. The masochistic stance entails loving someone who treats them poorly, because suffering is seen as the only way of maintaining a connection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/29\">",
"     29",
"    </a>",
"    ]. Sadism and masochism always co-exist in individuals, and may alternate in ascendance or present simultaneously. As an example, someone may be submissive and long-suffering (masochistic), but at the same time use that passivity to control and undermine a significant other (sadism).",
"   </p>",
"   <p>",
"    To maintain a relationship with a patient with a sadomasochistic interpersonal style, the therapist must constantly assess whether &ldquo;attacks&rdquo; represent a rupture in the therapeutic relationship that needs to be addressed or simply a need to give voice to tremendous anger. In the instances where the relationship appears to be in jeopardy, the therapist should discuss the patient&rsquo;s reaction to the therapist&rsquo;s interventions, acknowledging his or her distress and telling him or her that the therapist would reflect on what had led him or her to make the offending comments. The therapist must withstand being portrayed as bad or incompetent in the patient&rsquo;s mind without retaliating as though it were true.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284922\">",
"    <span class=\"h2\">",
"     Cluster C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     &ldquo;anxious/fearful&rdquo;",
"    </span>",
"    cluster is comprised of dependent, avoidant, and obsessive-compulsive personality disorders. Patients with Cluster C disorders are emotionally inhibited and averse to interpersonal conflict and are often considered to be the most treatable on the spectrum of personality disorders. These patients frequently feel very guilty and internalize blame for situations even when it is clear there is none. Building a therapeutic relationship is more easily facilitated because these patients are somewhat more capable and willing to take responsibility for their problems and more readily engage in a dialogue with the therapist to try to solve them, compared with patients with more severe Cluster A or B disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/25\">",
"     25",
"    </a>",
"    ]. The inhibited agency of some of these patients leads them to behave in a passive-aggressive manner rather than confront situations directly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284929\">",
"    <span class=\"h3\">",
"     Dependent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fearing abandonment, dependent patients tend to be passive, submissive, and in need of constant reassurance. They go to great lengths not to offend others, even at great emotional expense, agreeing with others&rsquo; opinions when they really do not, or volunteering to do unsavory things to stay in someone&rsquo;s good graces. In the context of treatment, dependent patients are easily engaged, at least superficially, but they often withhold a great deal of personal information for fear of alienating or offending the therapist in some way.",
"   </p>",
"   <p>",
"    One difficulty in working in psychotherapy with such patients is the reinforcement gained by the patient&rsquo;s behavior. That is, because passivity and submissiveness usually result in being taken care of, dependent patients are loath to see the value in asserting independence. Dependent patients assume that they are actually incapable of functioning independently and that being assertive will be experienced by others as alienating aggressiveness. A therapist must be alert to the potential for the patient to withdraw emotionally and psychologically (such as withholding information) which is a typical manifestation of strain or rupture with this type of pathology. Additional challenges to the therapeutic relationship may occur when the therapist attempts to encourage more independence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284936\">",
"    <span class=\"h3\">",
"     Avoidant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The avoidant individual is interpersonally sensitive, afraid of being criticized, and constantly concerned about saying or doing something foolish or humiliating. In spite of an intense desire to connect with others, an avoidant person does not let anyone get close unless absolutely sure of being liked. Because of this acute sensitivity, avoidant patients can be difficult to retain in treatment. A study of 38 patients receiving a short-term supportive-expressive psychotherapy found that patients with avoidant personality disorder were significantly more likely to drop out compared to patients with obsessive-compulsive personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/30\">",
"     30",
"    </a>",
"    ]. Clinicians who work with avoidant patients need to be constantly mindful of the potentially shaming effects of certain comments that are taken as criticisms, but can also work with the patient&rsquo;s underlying desire for attachment to enlist them in building a relationship.",
"   </p>",
"   <p>",
"    At least some patients diagnosed with avoidant personality disorder are actually better characterized as vulnerable narcissists. These patients covertly crave admiration to bolster their fragile self-esteem and secretly or unconsciously feel entitled to it, rather than simply being afraid of not being liked or accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/31\">",
"     31",
"    </a>",
"    ]. This style has been referred to as hypervigilant narcissism, emphasizing extreme interpersonal sensitivity, other-directedness, and shame proneness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/27\">",
"     27",
"    </a>",
"    ]. Unrecognized narcissism in avoidant personality disorder has significant treatment implications, as described above in the treatment of narcissistic personality disorder. (See",
"    <a class=\"local\" href=\"#H25284894\">",
"     'Narcissistic'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Avoidant personality disorder is frequently seen as very similar to",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    co-occurring with social anxiety disorder. However, individuals with avoidant personality disorder are typically more broadly and severely impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/32\">",
"     32",
"    </a>",
"    ]. In avoidant personality disorder, the hypersensitivity to social evaluation is associated with a core belief that the self is inferior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284943\">",
"    <span class=\"h3\">",
"     Obsessive-compulsive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obsessive-compulsive character is associated with more stable interpersonal relationships than some other personality styles, but individuals with this style are often unaware of their emotions, have very limited ways of functioning in the world, and deny interpersonal and psychological conflicts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/33\">",
"     33",
"    </a>",
"    ]. Self-willed and obstinate, with attention to rules and regulations, people with obsessive-compulsive attributes guard against meaningful consideration of their motives toward others.",
"   </p>",
"   <p>",
"    Maintaining control over internal experience and the external world is a top priority, so rigidity is often a hallmark of this character type. Except in its most severe manifestations, obsessive-compulsive character pathology is less impairing than some of the others, and more readily ameliorated by treatment. Although stubborn and controlling and averse to considering emotional content, obsessive-compulsive individuals also generally try to be &ldquo;good patients&rdquo; and so can be engaged in a constructive therapeutic relationship that is less problematic compared with other types of personality disorder patients.",
"   </p>",
"   <p>",
"    Obsessive-compulsive personality disorder (OCPD) is distinct from obsessive-compulsive disorder (OCD), an anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/34\">",
"     34",
"    </a>",
"    ]. In contrast to OCPD, described above, OCD is manifested by the patient&rsquo;s experience of obsessive thoughts and compulsive behaviors. There is only modest co-occurrence between OCPD and OCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284950\">",
"    <span class=\"h3\">",
"     Passive-aggressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The passive-aggressive (negativistic) personality disorder diagnosis was included in Cluster C in DSM-III-R [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/35\">",
"     35",
"    </a>",
"    ], but was subsequently shifted to the appendix of disorders needing further study in DSM-IV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/36\">",
"     36",
"    </a>",
"    ]. In our experience, we find this diagnosis to be clinically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3896/abstract/37\">",
"     37",
"    </a>",
"    ]. Like sadomasochism, passive-aggressive tendencies may be present across many personality disorder types.",
"   </p>",
"   <p>",
"    Passive-aggressive traits include argumentativeness, scorning authority, resistance to carrying out social and occupational responsibilities, angry pessimism, alternating between defiance and contrition, envy, and exaggerated complaints about personal misfortune. These attributes pose challenges to the formation of an effective therapeutic relationship because these patients are likely to expect that the treatment holds no promise of helping, and they behave in ways that contribute to that outcome. &nbsp;It is important for the clinician to tolerate these difficult stances and help the patient to explore and understand why he or she may be engaging in such behaviors, whether it be because of discomfort with self-assertion due to fear of rejection or punishment, or perhaps as a means of trying to protect one&rsquo;s autonomy through thwarting others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25284426\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients entering psychotherapy should be assessed for personality style, pathology, or disorder. Individuals with personality disorders will manifest disturbed patterns of interpersonal relations that can have a deleterious effect on the therapeutic relationship if not addressed by the therapist. (See",
"      <a class=\"local\" href=\"#H25284827\">",
"       'Personality disorders and traits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      People with schizotypal, schizoid, and paranoid personality disorders (Cluster A) often do not readily seek treatment unless dealing with acute problems such as substance abuse. For those who do seek treatment, there is evidence that these patients have great difficulty establishing a therapeutic relationship. (See",
"      <a class=\"local\" href=\"#H25284852\">",
"       'Cluster A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Borderline, narcissistic, histrionic, and antisocial personality disorders (Cluster B) are each associated with testing and pushing the limits of the treatment relationship. Clinicians need to take great care to avoid crossing appropriate boundaries in a quest to build a relationship. Many Cluster B patients present the most daunting challenges to maintaining a therapeutic relationship. (See",
"      <a class=\"local\" href=\"#H25284880\">",
"       'Cluster B'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20615?source=see_link&amp;anchor=H14925268#H14925268\">",
"       \"Establishing and maintaining a therapeutic relationship in psychiatric practice\", section on 'Boundary crossings and violations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Building a therapeutic relationship with patients with dependent, avoidant, and obsessive-compulsive personality disorders (Cluster C) is facilitated because these patients are willing to take responsibility for their problems and more readily engage in a dialogue with the therapist to try to solve them in comparison to patients with more severe Cluster A or B disorders. (See",
"      <a class=\"local\" href=\"#H25284922\">",
"       'Cluster C'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Orlinsky DA, Grawe K, Parks BK. Process and outcome in psychotherapy: Noch einmal. In: Handbook of Psychotherapy and Behavior Change, 4th ed, Bergin AE, Garfield SL.  (Eds), Wiley, New York 1994. p.270.",
"    </li>",
"    <li>",
"     The Working Alliance: Theory, Research, and Practice, Horvath AO, Greenberg LS.  (Eds), Wiley, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/3\">",
"      Horvath AO, Symonds BD. Relation between working alliance and outcome in psychotherapy: a meta-analysis. J Couns Psychol 1991; 38:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/4\">",
"      Horvath AO, Del Re AC, Fl&uuml;ckiger C, Symonds D. Alliance in individual psychotherapy. Psychotherapy (Chic) 2011; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/5\">",
"      Bender DS, Morey LC, Skodol AE. Toward a model for assessing level of personality functioning in DSM-5, part I: a review of theory and methods. J Pers Assess 2011; 93:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/6\">",
"      Connolly Gibbons MB, Crits-Christoph P, de la Cruz C, et al. Pretreatment expectations, interpersonal functioning, and symptoms in the prediction of the therapeutic alliance across supportive-expressive psychotherapy and cognitive therapy. Psychother Res 2003; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/7\">",
"      Hersoug AG, Monsen JT, Havik OE, H&oslash;glend P. Quality of early working alliance in psychotherapy: diagnoses, relationship and intrapsychic variables as predictors. Psychother Psychosom 2002; 71:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/8\">",
"      Piper WE, Azim HF, Joyce AS, et al. Quality of object relations versus interpersonal functioning as predictors of therapeutic alliance and psychotherapy outcome. J Nerv Ment Dis 1991; 179:432.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/10\">",
"      McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand 2000; 102:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/11\">",
"      Horvath AO, Luborsky L. The role of the therapeutic alliance in psychotherapy. J Consult Clin Psychol 1993; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/12\">",
"      Gunderson JG, Najavits LM, Leonhard C, et al. Ontogeny of the therapeutic alliance in borderline patients. Psychother Res 1997; 7:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/13\">",
"      Lingiardi V, Filippucci L, Baiocco R. Therapeutic alliance evaluation in personality disorders psychotherapy. Psychother Res 2005; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/14\">",
"      Bender DS, Farber BA, Sanislow CA, et al. Representations of therapists by patients with personality disorders. Am J Psychother 2003; 57:219.",
"     </a>",
"    </li>",
"    <li>",
"     Benjamin LS. Interpersonal Diagnosis and Treatment of Personality Disorders, 2nd ed, Guilford, New York 1996.",
"    </li>",
"    <li>",
"     Akhtar S. Broken Structures: Severe Personality Disorders and Their Treatment, Jason Aronson, Northvale, NJ 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/17\">",
"      Safran JD, Muran JC, Eubanks-Carter C. Repairing alliance ruptures. Psychotherapy (Chic) 2011; 48:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/18\">",
"      Kernberg O. Borderline personality organization. J Am Psychoanal Assoc 1967; 15:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/19\">",
"      Diamond D, Stovall-McClough C, Clarkin JF, Levy KN. Patient-therapist attachment in the treatment of borderline personality disorder. Bull Menninger Clin 2003; 67:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/20\">",
"      Waldinger RJ, Gunderson JG. Completed psychotherapies with borderline patients. Am J Psychother 1984; 38:190.",
"     </a>",
"    </li>",
"    <li>",
"     Horwitz L, Gabbard GO, Allen JG, et al. Borderline Personality Disorder: Tailoring the Psychotherapy to the Patient, American Psychiatric Press, Washington, DC 1996.",
"    </li>",
"    <li>",
"     Kohut H. The Restoration of the Self, International Universities Press, New York 1977.",
"    </li>",
"    <li>",
"     Kernberg OF. Severe Personality Disorders: Psychotherapeutic Strategies, Yale University Press, New Haven, CT 1984.",
"    </li>",
"    <li>",
"     Meissner WW. The Therapeutic Alliance, Yale University Press, New Haven, CT 1996.",
"    </li>",
"    <li>",
"     Stone MH. Abnormalities of Personality, WW Norton, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/26\">",
"      Gerstley L, McLellan AT, Alterman AI, et al. Ability to form an alliance with the therapist: a possible marker of prognosis for patients with antisocial personality disorder. Am J Psychiatry 1989; 146:508.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard GO. Psychodynamic Psychiatry in Clinical Practice, 4th ed, American Psychiatric Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     Bach S. The Language of Perversion and the Language of Love, Jason Aronson, Northvale, NJ 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/29\">",
"      BERLINER B. The role of object relations in moral masochism. Psychoanal Q 1958; 27:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/30\">",
"      Barber JP, Morse JQ, Krakauer ID, et al. Change in obsessive-compulsive and avoidant personality disorders following time-limited supportive-expressive therapy. Psychotherapy 1997; 34:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/31\">",
"      Dickinson KA, Pincus AL. Interpersonal analysis of grandiose and vulnerable narcissism. J Pers Disord 2003; 17:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/32\">",
"      Hummelen B, Wilberg T, Pedersen G, Karterud S. The relationship between avoidant personality disorder and social phobia. Compr Psychiatry 2007; 48:348.",
"     </a>",
"    </li>",
"    <li>",
"     Shapiro D. Neurotic Styles, Basic Books, New York 1965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/34\">",
"      Mancebo MC, Eisen JL, Grant JE, Rasmussen SA. Obsessive compulsive personality disorder and obsessive compulsive disorder: clinical characteristics, diagnostic difficulties, and treatment. Ann Clin Psychiatry 2005; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3896/abstract/37\">",
"      Wetzler S, Morey LC. Passive-aggressive personality disorder: the demise of a syndrome. Psychiatry 1999; 62:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16980 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3896=[""].join("\n");
var outline_f3_51_3896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25284426\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89663711\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25284827\">",
"      PERSONALITY DISORDERS AND TRAITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25284852\">",
"      Cluster A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284859\">",
"      - Schizotypal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284866\">",
"      - Schizoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284873\">",
"      - Paranoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25284880\">",
"      Cluster B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284887\">",
"      - Borderline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284894\">",
"      - Narcissistic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284901\">",
"      - Histrionic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284908\">",
"      - Antisocial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284915\">",
"      - Sadomasochistic character",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25284922\">",
"      Cluster C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284929\">",
"      - Dependent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284936\">",
"      - Avoidant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284943\">",
"      - Obsessive-compulsive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25284950\">",
"      - Passive-aggressive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25284426\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/50/5933\" title=\"table 1\">",
"      Alliance-relevant aspects of personality disorder styles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=related_link\">",
"      Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=related_link\">",
"      Borderline personality disorder: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20615?source=related_link\">",
"      Establishing and maintaining a therapeutic relationship in psychiatric practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3769?source=related_link\">",
"      Treatment of antisocial personality disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_51_3897="Opioid intoxication in adults";
var content_f3_51_3897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Opioid intoxication in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Andrew Stolbach, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Robert S Hoffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3897/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/51/3897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opiates extracted from the poppy plant (Papaver somniferum) have been used recreationally and medicinally for millennia. Opiates belong to the larger class of drugs, the opioids, which include synthetic and semi-synthetic drugs, as well. Opioid abuse is a worldwide problem and deaths from opioid overdose are numerous and increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the mechanisms, clinical manifestations, and management of acute opioid intoxication. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef55540 \" href=\"UTD.htm?5/7/5245\">",
"     table 1",
"    </a>",
"    ). Issues related to opioid withdrawal, chronic opioid abuse, and general management of the poisoned patient are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opioid pharmaceuticals are analogous to the three families of endogenous opioid peptides: enkephalins, endorphins, and dynorphin. The most recent classification scheme identifies three major classes of opioid receptor, with several minor classes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/5\">",
"     5",
"    </a>",
"    ]. Within each receptor class there are distinct subtypes. Each subtype produces a variety of distinct clinical effects, although there is some overlap (",
"    <a class=\"graphic graphic_table graphicRef64386 \" href=\"UTD.htm?15/2/15404\">",
"     table 2",
"    </a>",
"    ). For most clinicians, the nomenclature derived from the Greek alphabet is more familiar, although the International Union of Pharmacology (IUPHAR) Committee on Receptor Nomenclature has recommended a change from the original Greek system to make opioid receptor names more consistent with other neurotransmitter systems [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The opioid receptors are distinct in their locations and clinical effects, but they are structurally similar (",
"    <a class=\"graphic graphic_table graphicRef64386 \" href=\"UTD.htm?15/2/15404\">",
"     table 2",
"    </a>",
"    ). Each consists of seven transmembrane segments, with amino acid and carboxy termini. Although the opioid receptors are all coupled to G proteins, they use a variety of signal transduction mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/5\">",
"     5",
"    </a>",
"    ]. These include reducing the capacity of adenylate cyclase to produce cAMP, closing calcium channels that reduce the signal to release neurotransmitters, or opening potassium channels to hyperpolarize the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The end result of these mechanisms is to modulate the release of neurotransmitters. Opioid receptors exist throughout the central and peripheral nervous system and are linked to a variety of neurotransmitters, which explains the diversity of their clinical effects. The analgesic effects of opioids result from inhibition of nociceptive information at multiple points of its transmission from the peripheral nerve to the spinal cord to the brain. Euphoria results from increased dopamine released in the mesolimbic system [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/6\">",
"     6",
"    </a>",
"    ]. Anxiolysis results from effects on noradrenergic neurons in the locus ceruleus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast number of opioids precludes presenting pharmacokinetic data for each one, but a few clinically important generalizations can be made. The majority of opioids have volumes of distribution of 1 to 10",
"    <span class=\"nowrap\">",
"     L/kg,",
"    </span>",
"    which makes removal of a significant quantity of drug by hemodialysis impossible. They have variable protein binding (from 89 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    to 7.1 percent for hydrocodone) and are renally eliminated. Many opioids are metabolized by the liver to active metabolites. Examples include hydrocodone (metabolized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    by Cytochrome [CY] P2D6) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (metabolized to morphine-6-glucuronide). Cytochrome P polymorphisms cause variations in clinical effect.",
"   </p>",
"   <p>",
"    The most clinically important pharmacokinetic difference is a wide variation in serum half-life (",
"    <a class=\"graphic graphic_table graphicRef70480 \" href=\"UTD.htm?1/2/1070\">",
"     table 3",
"    </a>",
"    ). The half-life data in these tables, taken from healthy subjects receiving therapeutic doses, should serve only as a rough guide to duration of clinical effect. Actual effects are influenced by dose, an individual's tolerance, and the presence of active metabolites.",
"   </p>",
"   <p>",
"    In overdose the serum half-life may vary significantly from therapeutic dosing. If many tablets are taken, dissolution and absorption will be delayed, prolonging the apparent half-life. Duration of action may also be shortened in overdose. As an example, when a sustained-release formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    is crushed before ingestion, the drug is rapidly absorbed. While the user's intent may be to increase euphoria, the chance of significant morbidity is increased as well.",
"   </p>",
"   <p>",
"    Although active metabolites of some opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) may accumulate in patients with renal insufficiency, such metabolites are not dialyzable and management is unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important clinical features related to opioid intoxication are discussed here. A general approach to the overdose patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should attempt to identify the specific drug, dose, and formulation to which the patient was exposed, the presence of nonopioid coexposures, and the individual's prior history of opioid use. One review found the \"typical\" heroin death to involve experienced users in their 20s to 30s using coingestants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/9\">",
"     9",
"    </a>",
"    ]. While not essential for management, historical features may help predict the expected duration of poisoning. History should also determine the reason for poisoning, as the patient's intention will influence post-overdose management. Generally, opioid exposures will fall into one of several categories: therapeutic use, recreational use, intended self-harm, attempt to hide drugs from law enforcement out of fear for arrest (\"body stuffing\"), swallowing large quantities of packaged drugs in order to transport them across borders (\"body packing\"), and unintentional pediatric exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination helps to confirm the diagnosis of opioid poisoning, determine the extent of intoxication, identify other conditions requiring treatment, and prevent further exposure (",
"    <a class=\"graphic graphic_table graphicRef77213 \" href=\"UTD.htm?10/5/10331\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The classic signs of opioid intoxication include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Decreased respiratory rate",
"     </li>",
"     <li>",
"      Decreased tidal volume",
"     </li>",
"     <li>",
"      Decreased bowel sounds",
"     </li>",
"     <li>",
"      Miotic (constricted) pupils",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal pupil examination does",
"    <strong>",
"     not",
"    </strong>",
"    exclude opioid intoxication. Users of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/10\">",
"     10",
"    </a>",
"    ] and propoxyphene may present with normal pupils, and the presence of coingestants (such as sympathomimetics or anticholinergics) may make pupils appear normal or large. The best predictor of opioid poisoning is a respiratory rate &lt;12, which predicted response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    in virtually all patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinician should measure the respiratory rate and pay close attention to chest wall excursion, as subtle changes may not be identified in triage vital signs.",
"   </p>",
"   <p>",
"    While decreased respiratory rate is the most notable vital sign abnormality, heart rate ranges from normal to low, although this is not usually consequential. Mild hypotension (from histamine release) may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/12\">",
"     12",
"    </a>",
"    ]. Pulse oximetry should be performed in every patient, although the clinician should be wary that hypercapnia can be present in the setting of normal oxygen saturation, particularly when the patient is placed on supplemental oxygen.",
"   </p>",
"   <p>",
"    Obtain a core temperature from any patient more than mildly intoxicated. Hypothermia, which results from a combination of environmental exposure and impaired thermogenesis, may be present. In a severely obtunded patient, room temperature may produce significant hypothermia. Elevated temperature may suggest early aspiration pneumonia or complications of injection drug use, such as endocarditis.",
"   </p>",
"   <p>",
"    Mental status can range from euphoria to coma, or may be nearly normal. Seizures can occur in the setting of propoxyphene,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    exposure, or as a result of hypoxia from any opioid.",
"   </p>",
"   <p>",
"    During the secondary survey, look for signs of trauma, particularly to the head. Not only do opioids predispose the patient to trauma, but obtundation from traumatic brain injury can be misidentified as drug intoxication. Pulmonary findings, such as rales, can indicate the presence of aspiration or acute lung injury. If the patient is suspected of attempting to hide drugs out of fear for arrest, rectal and vaginal examination should be performed with the patient's permission. If the patient cannot give consent because of poisoning, consent is inferred based on medical necessity. Examination of the skin may identify medication patches that must be removed, track marks suggesting history of chronic injection drug use, or coexisting soft tissue infections (",
"    <a class=\"graphic graphic_picture graphicRef86745 \" href=\"UTD.htm?6/21/6482\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxicities of specific agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the general features described above, some agents have specific toxicities. A brief description of the notable, albeit infrequent, effects and characteristics of several opioids commonly encountered in the overdose patient follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      &ndash; Partial opioid agonist, may induce withdrawal in opioid-dependent patients",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       Dextromethorphan",
"      </a>",
"      &ndash; Serotonin syndrome, at high doses exhibits some &micro; effects of opioids (miosis, respiratory and CNS depression), but is not a pure opioid agonist",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      &ndash; Very short acting",
"     </li>",
"     <li>",
"      Hydrocodone &ndash; Often combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      &ndash; Seizure, serotonin syndrome (in combination with other agents) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      &ndash; Very long-acting; QTc prolongation, Torsades de Pointes (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocardiography'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      &ndash; Often combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ; possible QTc interval prolongation",
"     </li>",
"     <li>",
"      Propoxyphene &ndash; QRS prolongation, seizure",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      &ndash; Seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of opioid intoxication includes toxic and nontoxic conditions.",
"   </p>",
"   <p>",
"    There are myriad drugs that can produce coma (",
"    <a class=\"graphic graphic_table graphicRef59515 \" href=\"UTD.htm?21/48/22284\">",
"     table 5",
"    </a>",
"    ). Ethanol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , and sedative-hypnotics (eg, benzodiazepines) may be the most clinically-relevant toxic agents in the differential diagnosis, because they are so frequently seen. While clonidine may produce miosis and obtundation, bradycardia, and hypotension are more prominent. Ethanol intoxication produces little to no miosis and no change in bowel sounds. The sedative-hypnotic agents result in much less respiratory depression than the opioids, especially when taken orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of coingestants often confounds the diagnosis of opioid intoxication. While it is frequently impossible to determine the exact substances to which the patient was exposed, a careful history, physical examination, and judicious use of laboratory studies can determine the correct course of management. The sine qua non of opioid intoxication is clinical response to an antagonist, although giving large doses of antagonist to establish the diagnosis of opioid poisoning is usually not helpful and potentially dangerous, and therefore not recommended. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any medical condition that can produce coma may be mistaken for (or occur in conjunction with) opioid poisoning. The most important conditions to exclude are those in which delay of diagnosis will delay definitive care, such as cerebrovascular accident, electrolyte abnormality, and sepsis (",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"UTD.htm?39/19/40254\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION AND ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid serum glucose concentration should be obtained in all suspected cases of opioid overdose. Hypoglycemia is prevalent, easily detectable, rapidly correctable, and potentially confused with opioid poisoning. Most patients with mild or moderate unintentional or recreational poisoning can be managed successfully without any further laboratory investigation.",
"   </p>",
"   <p>",
"    After any overdose in which the opioid is formulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , or any overdose that is the result of intended self-harm, serum acetaminophen concentration should be obtained. In one series, 1 in 365 individuals with suicidal ingestion and history negative for acetaminophen ingestion had a potentially hepatotoxic acetaminophen concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/13\">",
"     13",
"    </a>",
"    ]. It is not essential to obtain a salicylate concentration in the absence of clinical suspicion or signs of overdose (eg, tachypnea or increased anion gap). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To exclude rhabdomyolysis in the patient presenting after prolonged immobilization, serum creatine phosphokinase concentration should be obtained. Further testing, such as serum creatinine and electrolytes, may be needed depending on clinical circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512176#H11512176\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine toxicologic screens should",
"    <strong>",
"     NOT",
"    </strong>",
"    be routinely obtained. Acute opioid poisoning is a clinical diagnosis; the management of a patient with an opioid toxidrome is unchanged by the result of a urine opioid screen. A positive test may indicate recent use but not current intoxication, or may even represent a false positive. Conversely, many opioids, especially the synthetic drugs, will produce false-negative results in many commonly available urine screens. Commonly available laboratory assays (eg, for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ) can be performed if the history or examination suggests coingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be obtained when the patient is suspected of intended self-harm or a coexposure likely to cause cardiovascular complications is possible (eg, cocaine or a cyclic antidepressant). With a few exceptions, electrocardiography can be omitted in other types of opioid exposure.",
"   </p>",
"   <p>",
"    Propoxyphene is unique among the opioids for its type IA antidysrhythmic properties. Prolongation of the QRS interval can occur and is responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Specific agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    can cause QTc interval prolongation and Torsades de Pointes. This phenomenon more commonly occurs in patients taking high daily doses of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the observations that most people who take very large doses of methadone tolerate it well and that some have developed QTc prolongation from lower doses suggest individual susceptibility to the condition varies. There may also&nbsp;be an association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    toxicity and QTc prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of performing an ECG on every individual with a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    exposure is unstudied and cannot be recommended. Rather, the test should generally be reserved for those patients presenting after a large dose increase&nbsp;or with complaints suggesting a dysrhythmia, such as palpitations or syncope. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Specific agents'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is reserved for those patients with adventitious lung sounds or hypoxia that does not correct when ventilation is addressed. Abnormal lung sounds may represent aspiration pneumonia or acute lung injury. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Acute lung injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Imaging of drug packets is discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Body packing and body stuffing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Basic measures and antidotal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;General management of the overdose patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .) Specific management strategies for opioid overdose are discussed below. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef55540 \" href=\"UTD.htm?5/7/5245\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once opioid poisoning is suspected, initial management should focus on support of the patient's airway and breathing. Attention should be paid to the depth and rate of ventilation. While pulse-oximetry is useful in monitoring oxygenation, it may not be useful in gauging ventilation when supplemental oxygen is being given. While not yet widely used for this purpose, capnography may prove to be an excellent tool to monitor the ventilatory effort of opioid-poisoned patients. Several studies in patients undergoing procedural sedation show that ventilatory difficulty manifests as elevations in end-tidal CO2 earlier than declines in oxygenation by pulse oximetry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , a short-acting opioid antagonist, by the intravenous route. The apneic patient and patients with extremely low respiratory rates or shallow respirations should be ventilated by bag-valve mask attached to supplemental oxygen prior to and during naloxone administration to reduce the chance of acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/17\">",
"     17",
"    </a>",
"    ]. Apneic patients should receive higher initial doses of naloxone (0.2 to 1 mg). Patients in cardiorespiratory arrest following possible opioid overdose should be given a minimum of 2 mg of naloxone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Acute lung injury'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When spontaneous ventilations are present, an initial dose of 0.05 mg is an appropriate starting point, and the dose should be titrated upward every few minutes until the respiratory rate is 12 or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/20\">",
"     20",
"    </a>",
"    ]. The goal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    administration is",
"    <strong>",
"     NOT",
"    </strong>",
"    a normal level of consciousness, but adequate ventilation. In the absence of signs of opioid withdrawal, there is no maximum safe dose of naloxone. However, if a clinical effect does not occur after 5 to 10 mg, the diagnosis should be reconsidered.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    may be given subcutaneously or intramuscularly if there is a delay in securing intravenous access. When given by these routes, there is slower absorption and delayed elimination, making the drug much more difficult to titrate. Naloxone can be absorbed in the respiratory tract, and thus can be administered into an endotracheal tube or nebulized. Conceptually, there is little role for nebulized or nasal naloxone because the dose administered is determined by the patient's ventilation, thus the most severely poisoned patients will absorb the least amount of antidote [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/21\">",
"     21",
"    </a>",
"    ]. The respiratory route and other routes of administration are less predictable. In addition, intravenous access is required in these patients as other medications (such as hypertonic dextrose) may be needed.",
"   </p>",
"   <p>",
"    If the clinician \"overshoots\" the appropriate dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    in an opioid-dependent individual, withdrawal will ensue. Symptoms of withdrawal should be managed expectantly only,",
"    <strong>",
"     NOT",
"    </strong>",
"    with opioids. To overcome naloxone antagonism requires a large dose of opioids. More importantly, because naloxone has a short duration of action, any opioid administered will result in even more sedation once naloxone's effects subside. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After ventilation is restored with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , repeat doses may be required, depending on the quantity and duration of action of the opioid. As an alternative to repeat dosing, a naloxone infusion can be prepared by determining the total initial dose required to reinstate breathing, and delivering two thirds of that dose every hour [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/22\">",
"     22",
"    </a>",
"    ]. If the patient develops withdrawal signs or symptoms during the infusion, stop the infusion. If intoxication returns, restart the infusion at half the initial rate. If the patient develops respiratory depression during the infusion, readminister half the initial bolus every few minutes until symptoms improve, then increase the infusion by half the initial rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     GI decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    and gastric emptying are almost never indicated in opioid poisoning. Gastrointestinal decontamination is not without risk and opioid poisoning is readily treatable by other means. While orogastric lavage could remove tablets still in the stomach, and activated charcoal binds opioids, each of these therapies produces a risk of aspiration, especially in the obtunded, opioid-poisoned patient. Gastrointestinal decontamination should be reserved for patients presenting with potentially life-threatening coingestants, not for opioids alone, and should be performed only if the airway is secure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large volume of distribution of the opioids precludes removal of a significant quantity of drug by hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Body packing and body stuffing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packing is described as the act of swallowing packets or containers of drug for the purposes of smuggling. Body packers are generally participants in international drug networks who are transporting drugs across international borders. Heroin and cocaine are more frequently implicated than other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/23\">",
"     23",
"    </a>",
"    ]. The smugglers carry massive amounts of well-packaged drugs. While the majority of body packers do not present to health care, those who do should be evaluated for signs of intoxication (from ruptured or leaking packets), obstruction, or, rarely, gastrointestinal perforation. A detailed discussion of body packing is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain radiography has a sensitivity of 85 to 90 percent for finding packets [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/24\">",
"     24",
"    </a>",
"    ]. Computed tomography of the abdomen will be more sensitive, as well as offer the ability to identify complications, such as obstruction or perforation. A negative urine screen may be useful to exclude the presence of ruptured packets.",
"   </p>",
"   <p>",
"    If the history reveals that the patient has smuggled packets of heroin, the goals of management are to support the airway and assist in elimination of the packets. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    should be given until ventilation is adequate. The total dose required should be given hourly to preserve the effect. The dose requirement may increase if further packet rupture or leakage occurs.",
"   </p>",
"   <p>",
"    After confirming bowel sounds, polyethylene glycol electrolyte lavage solution (PEG-ELS) should be administered orally at a rate of 2",
"    <span class=\"nowrap\">",
"     L/h",
"    </span>",
"    until all packets have been passed. Though placement of a nasogastric tube is not necessary (and should be avoided in the patient with a depressed mental status), it may facilitate administration of the solution.",
"   </p>",
"   <p>",
"    Operative management will be required only if gastrointestinal obstruction or perforation occur.",
"   </p>",
"   <p>",
"    \"Body stuffing\" refers to the swallowing of a smaller quantity of drug because of fear of arrest. Compared with body packers, body stuffers are carrying a far smaller quantity of drug and the drug is more poorly packaged. In contrast to the \"body packer\", it may not be necessary to routinely administer PEG-ELS to the opioid \"body stuffer\". While the regimen could theoretically cause some packages to pass before drug is absorbed, the clinician may elect to manage the patient by close observation and administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    if symptoms arise.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Oral activated charcoal",
"    </a>",
"    alone may be sufficient.",
"   </p>",
"   <p>",
"    The body stuffer should be observed for signs of intoxication. The ideal length of time is not known, but 6 to 12 hours is reasonable. If signs of opioid poisoning develop, the patient can be managed as described above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute lung injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lung injury (ALI) is a potential adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , heroin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , and other opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The signs, which typically include rales, hypoxia, and occasionally frothy sputum, often occur as a patient is recovering from opioid-induced respiratory depression. The pathophysiology is unclear, but in some cases ALI occurs in the setting of iatrogenic reversal of opioid toxicity (such as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    ). In such cases, rapid precipitation of withdrawal in the setting of elevated PCO2 may cause a surge in catecholamine concentrations, thereby increasing afterload, which causes interstitial edema followed by alveolar filling [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/17\">",
"     17",
"    </a>",
"    ]. Because of this, very small doses of naloxone (0.05 mg to start) should be used on those patients with marked hypoventilation and they should be ventilated with a bag-valve mask prior to administration of naloxone. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Basic measures and antidotal therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of opioid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    -related acute lung injury (ALI) is supportive and the prognosis is generally good if it is identified and addressed promptly. The clinical manifestations and management of ALI are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Specific agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several opioids possess uncommon toxicities requiring specific management. Propoxyphene is unique among the opioids for its type IA antidysrhythmic properties. Prolongation of the QRS interval can occur and is responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/14\">",
"     14",
"    </a>",
"    ]. The clinical benefit of this intervention is unknown, but if QRS prolongation is encountered it seems reasonable to administer a bolus of 1 to 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    of sodium bicarbonate intravenously in the absence of contraindications. If the complex narrows, a bicarbonate infusion can be performed. We mix 132 mEq of NaHCO3 in 1 liter of D5W, and infuse at 250",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    can cause QTc interval prolongation and Torsades de Pointes. If the QTc is determined to be greater than 500 msec, the patient should be observed on a cardiac monitor for a 24-hour period and hypocalcemia, hypokalemia, and hypomagnesemia should be corrected when present. The clinician should consider either stopping methadone therapy, or switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , if the patient's psychosocial situation permits this. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Electrocardiography'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29872809\">",
"    <span class=\"h2\">",
"     Buprenorphine and naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is a partial agonist at the opioid receptor. When taken alone, buprenorphine can cause respiratory depression, but likely to a limited degree. Although most fatalities associated with buprenorphine have occurred in the setting of mixed overdose where the coingestant may produce or contribute to respiratory depression (eg, alcohol or benzodiazepines), fatalities may occur from buprenorphine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    binds to the opioid receptor with high affinity. In experimental models, high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    were needed to reverse respiratory depression. Interestingly, because of complex physiology, respiratory depression can recur with very high doses of naloxone. This effect has been described as a &ldquo;bell-shaped&rdquo; dose-response curve and may be a result of the high affinity of buprenorphine for the opioid receptor compared to naloxone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such research has led some to conclude that respiratory depression from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    may be difficult to reverse with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . In observational studies of buprenorphine toxicity, the response to naloxone is mixed. In a case series of patients with buprenorphine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    overdose, none of the 19 patients administered 0.4 to 0.8 mg of naloxone had an adequate response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, standard naloxone doses were adequate for reversal of buprenorphine effects in a small series of pediatric patients treated in an intensive care unit for buprenorphine toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3897/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that clinicians start with standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    doses (0.04 to 0.05 mg IV) when treating patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    -associated respiratory depression, but be prepared to titrate to higher doses (single doses of up to 2 mg, for a total of 10 mg) than are typically required to treat respiratory depression from other opioids. After initial reversal is achieved, a naloxone infusion may be preferable to serial boluses. Infusion dosing is described above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Basic measures and antidotal therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of overdoses involving the long-acting opioid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , most opioid poisonings can be managed in the emergency department without need for hospital admission. Generally, the patient may be discharged or transferred for psychiatric evaluation once respiration and mental status are normal and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    has not been administered for two to three hours. Although the half-life of naloxone is just over one hour, the duration of the drug's effect is shorter. Therefore, a two to three hour period of observation is generally sufficient.",
"   </p>",
"   <p>",
"    Management of opioid intoxication in children is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link\">",
"     \"Opioid intoxication in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pharmacology and presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a wide variation in the serum half-life of opioids (",
"      <a class=\"graphic graphic_table graphicRef70480 \" href=\"UTD.htm?1/2/1070\">",
"       table 3",
"      </a>",
"      ). Actual drug effects are influenced by dose, an individual's tolerance, and the presence of active metabolites. In overdose the serum half-life may vary significantly from therapeutic dosing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic signs of opioid intoxication include: depressed mental status, decreased respiratory rate, decreased tidal volume, decreased bowel sounds, and miotic pupils. The best predictor of opioid poisoning is a respiratory rate &lt;12. Normal pupil examination does",
"      <strong>",
"       NOT",
"      </strong>",
"      exclude opioid intoxication. Users of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      and propoxyphene may present with normal pupils; the presence of coingestants (such as sympathomimetics or anticholinergics) may make pupils appear normal or large. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although suppression of respiratory drive is most prominent, opioid intoxication can also be complicated by hypothermia, coma, seizure, head trauma, aspiration pneumonia, and rhabdomyolysis. Coingestants are frequently present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any medical condition that can produce coma may be mistaken for (or occur in conjunction with) opioid poisoning. The most important conditions to exclude are those in which delay of diagnosis will delay definitive care, such as intracranial hemorrhage, electrolyte abnormality, and sepsis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rapid serum glucose concentration should be obtained in all suspected cases of opioid overdose. Most patients with mild or moderate unintentional poisoning can be managed successfully without any further laboratory investigation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An electrocardiogram (ECG) should be obtained when the patient is suspected of intended self-harm or a coexposure likely to cause cardiovascular complications is possible. Propoxyphene can cause QRS prolongation;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      can cause QTc prolongation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Electrocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef55540 \" href=\"UTD.htm?5/7/5245\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial management should focus on support of the patient's airway and breathing. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Basic measures and antidotal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of suspected opioid overdose, we recommend the short-acting opioid antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      be given (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). While the intravenous (IV) route is preferred, naloxone may be given subcutaneously or intramuscularly if IV access is unavailable.",
"     </li>",
"     <li>",
"      When spontaneous ventilations are present, an initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      dose of 0.05 mg is an appropriate starting point, and the dose should be titrated upward every few minutes until the respiratory rate is 12 or greater. Bag mask ventilation should be performed prior to and during administration of naloxone in apneic patients and patients with very low respiratory rates or shallow respirations. Apneic patients should receive higher initial doses of naloxone (0.2 to 1 mg). Patients in cardiac arrest should receive a dose no less than 2 mg. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Basic measures and antidotal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      administration is",
"      <strong>",
"       NOT",
"      </strong>",
"      a normal level of consciousness, but adequate ventilation. In the absence of signs of opioid withdrawal, there is no maximum safe dose of naloxone. If a clinical effect does not occur after 5 to 10 mg, the diagnosis should be reconsidered. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Basic measures and antidotal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the clinician \"overshoots\" the appropriate dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      in an opioid-dependent individual, withdrawal will ensue. Symptoms of withdrawal should be managed expectantly only,",
"      <strong>",
"       NOT",
"      </strong>",
"      with opioids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"       \"Opioid withdrawal in the emergency setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Activated charcoal",
"      </a>",
"      and gastric emptying are almost never indicated in opioid poisoning. The large volume of distribution of the opioids precludes removal of a significant quantity of drug by hemodialysis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'GI decontamination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Extracorporeal removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, the patient may be discharged or transferred for psychiatric evaluation once respiration and mental status are normal and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      has not been administered for two to three hours. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/1\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings Office of Applied Studies, NSDUH Series H-28, DHHS Publication No. SMA 05-4062, Rockville, MD 2005.",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-28, DHHS Publication No. (SMA) 06-4143, Rockville, MD 2006.",
"    </li>",
"    <li>",
"     QuickStats: Number of Deaths From Poisoning,* Drug Poisoning,&dagger; and Drug Poisoning Involving Opioid Analgesics&sect; &mdash; United States, 1999&ndash;2010 www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a7.htm?s_cid=mm6212a7_e (Accessed on April 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/5\">",
"      Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/6\">",
"      Bonci A, Bernardi G, Grillner P, Mercuri NB. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 2003; 24:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/7\">",
"      Aghajanian GK, Wang YY. Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology 1987; 26:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/8\">",
"      Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/9\">",
"      Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/10\">",
"      Ghoneim MM, Dhanaraj J, Choi WW. Comparison of four opioid analgesics as supplements to nitrous oxide anesthesia. Anesth Analg 1984; 63:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/11\">",
"      Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991; 20:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/12\">",
"      Fahmy NR, Sunder N, Soter NA. Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther 1983; 33:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/13\">",
"      Ashbourne JF, Olson KR, Khayam-Bashi H. Value of rapid screening for acetaminophen in all patients with intentional drug overdose. Ann Emerg Med 1989; 18:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/14\">",
"      Stork CM, Redd JT, Fine K, Hoffman RS. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report. J Toxicol Clin Toxicol 1995; 33:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/15\">",
"      Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/16\">",
"      Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM 2013; 106:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/17\">",
"      Mills CA, Flacke JW, Flacke WE, et al. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth 1990; 37:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/18\">",
"      Berlot G, Gullo A, Romano E, Rinaldi A. Naloxone in cardiorespiratory arrest. Anaesthesia 1985; 40:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/19\">",
"      Bertini G, Russo L, Cricelli F, et al. Role of a prehospital medical system in reducing heroin-related deaths. Crit Care Med 1992; 20:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/20\">",
"      Osterwalder JJ. Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 1996; 34:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/21\">",
"      Dowling J, Isbister GK, Kirkpatrick CM, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008; 30:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/22\">",
"      Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986; 15:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/23\">",
"      Gill JR, Graham SM. Ten years of \"body packers\" in New York City: 50 deaths. J Forensic Sci 2002; 47:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/24\">",
"      Traub SJ, Hoffman RS, Nelson LS. Body packing--the internal concealment of illicit drugs. N Engl J Med 2003; 349:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/25\">",
"      Duberstein JL, Kaufman DM. A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema. Am J Med 1971; 51:704.",
"     </a>",
"    </li>",
"    <li>",
"     Osler W. Oedema of the left lung&mdash;morphia poisoning. Montreal General Hospital Reports Clinical and Pathological, vol 1, Dawson Bros Publishers, Montreal 1880. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/27\">",
"      Frand UI, Shim CS, Williams MH Jr. Methadone-induced pulmonary edema. Ann Intern Med 1972; 76:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/28\">",
"      Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/29\">",
"      van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006; 105:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/30\">",
"      M&eacute;garbane B, Buisine A, Jacobs F, et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010; 38:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3897/abstract/31\">",
"      Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med 2011; 12:e102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 300 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.150-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3897=[""].join("\n");
var outline_f3_51_3897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxicities of specific agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY EVALUATION AND ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Basic measures and antidotal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GI decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Body packing and body stuffing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Specific agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29872809\">",
"      Buprenorphine and naloxone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pharmacology and presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/300|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/21/6482\" title=\"picture 1\">",
"      Skin popping in substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/7/5245\" title=\"table 1\">",
"      Opioid intoxication in adults - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/2/15404\" title=\"table 2\">",
"      Opioid receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/2/1070\" title=\"table 3\">",
"      Common opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/5/10331\" title=\"table 4\">",
"      Examination findings in opioid poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/48/22284\" title=\"table 5\">",
"      Drugs causing coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40254\" title=\"table 6\">",
"      Causes of coma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_51_3898="Cluster headache: Acute and preventive treatment";
var content_f3_51_3898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cluster headache: Acute and preventive treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3898/contributors\">",
"     Arne May, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3898/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/51/3898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/51/3898/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/51/3898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache belongs to a group of idiopathic headache entities, the trigeminal autonomic cephalalgias (TACs), all of which involve short-lasting, unilateral, severe headache attacks and typical accompanying autonomic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/1\">",
"     1",
"    </a>",
"    ]. The concept of the TACs is useful for clinicians seeking a pathophysiologic understanding of the primary neurovascular headaches and a rational therapeutic approach to treating or preventing these headaches. Despite the diagnostic challenges, the short-lasting primary headaches are important to recognize because of their excellent but highly selective response to therapy.",
"   </p>",
"   <p>",
"    Currently, the treatment of cluster headache is based on empirical data rather than a clear understanding of the biologic mechanisms that underlie the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Drug treatment in cluster headache shows a placebo rate of about 30 percent, similar to that observed in migraine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, cluster headache treatment can be divided into acute therapy aimed at aborting individual attacks and prophylactic therapy aimed at preventing recurrent attacks during the cluster period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the treatment and prevention of cluster headache. Other aspects of cluster headache are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MORBIDITY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache is the most prominent of the trigeminal autonomic cephalalgias. It is recognized as so vicious that some patients attempt suicide if the disease is not diagnosed or successfully treated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ]. Although it is one of the most severe pain syndromes known to man, cluster headache remains underdiagnosed and suboptimally managed in primary care [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Furthermore, cluster headache results in marked functional disability, even when appropriate treatments are used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While data are limited, available evidence suggests that the proportion of patients experiencing attacks gradually declines with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Nevertheless, even 15 years after cluster headache onset, attacks still occur in 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    and oxygen inhalation are first-line treatments for acute cluster headache attack [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/11\">",
"     11",
"    </a>",
"    ]. Other agents with some evidence of effectiveness include ergots,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although controlled trial evidence is limited, oxygen therapy is considered to be safe and effective for aborting cluster headache.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind randomized trial evaluated 76 patients, each treating four cluster headache attacks, and compared 100 percent oxygen therapy (at 12",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      for 15 minutes) with air placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/12\">",
"       12",
"      </a>",
"      ]. By intention-to-treat analysis, pain-free status or adequate relief of attacks at 15 minutes was significantly more frequent with oxygen (78 percent of attacks, versus 20 percent with placebo).",
"     </li>",
"     <li>",
"      Two early small randomized trials found that inhalation of pure oxygen was beneficial for acute cluster headache attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Significant pain reduction was observed within 20 to 30 minutes in approximately 60 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, oxygen may be completely effective even when the pain is at maximal intensity, but in other cases the response is incomplete. Repeated or frequent oxygen intake in a short period of time should be avoided, because there is evidence that the attack frequency may increase in some patients with overuse of oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen (100 percent) is administered via a nonrebreathing facial mask with a flow rate of at least 12",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    with the patient in a sitting, upright position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ]. The inhalation should continue for 15 minutes to prevent the attack from returning, although the pain may subside as soon as five minutes after starting oxygen. Higher oxygen flow rates, up to 15",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    may sometimes be effective when standard rates are not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/17\">",
"     17",
"    </a>",
"    ]. From a practical standpoint, it is reasonable to increase the flow rate if lower rate is ineffective, as higher flow rate does not increase the risk of side effects.",
"   </p>",
"   <p>",
"    Oxygen is generally safe and without side effects. However, patients with severe chronic obstructive pulmonary disease should not be treated with inhaled oxygen because of the risk for developing severe hypercapnia and CO2 narcosis.",
"   </p>",
"   <p>",
"    Unlike normobaric oxygen therapy, hyperbaric oxygen is not widely available, and there are few studies evaluating its utility for abortive treatment of cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/15,18\">",
"     15,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized, double-blind, placebo-controlled trials have established that triptans, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    , are effective for the acute treatment of cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trials involving a combined total of 183 patients with cluster headache, subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      (6 mg) was beneficial (ie, pain-free within 20 minutes) in about 75 percent of patients, whereas the response rate for placebo was 25 to 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Sumatriptan was safe with no evidence of tachyphylaxis or rebound in most patients, even after frequent use [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      is effective for acute cluster headache. A randomized trial of 118 patients found a significantly higher response rate at 30 minutes with sumatriptan (20 mg) compared with placebo (57 versus 26 percent) and a higher 30 minute pain free rate (47 versus 18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/23\">",
"       23",
"      </a>",
"      ]. Although the intranasal route is more convenient, the speed of response with intranasal sumatriptan in this study was slower than that seen with subcutaneous sumatriptan in other studies.",
"     </li>",
"     <li>",
"      Intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      is another beneficial treatment option. In a randomized trial involving 69 patients available for intention-to-treat analysis, intranasal zolmitriptan at a dose of 5 or 10 mg was modestly effective at 30 minutes for acute cluster headache compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/24\">",
"       24",
"      </a>",
"      ]. Similar results were observed in a second trial involving 52 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/25\">",
"       25",
"      </a>",
"      ]. Of note, the intranasal dose of 10 mg of zolmitriptan has not been approved by the US Food and Drug Administration.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      10 mg was modestly effective for acute episodic (but not chronic) cluster headache within 30 minutes in another placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Limitations to use",
"    </span>",
"    &nbsp;&mdash;&nbsp;While triptans are generally well tolerated, uncomfortable side effects include nonischemic chest pain and distal paresthesia. It is still recommended that triptans be avoided in patients with ischemic cardiovascular disease or stroke, Prinzmetal's angina, uncontrolled arterial hypertension, or pregnancy. It may be prudent to give the first triptan dose under medical supervision for patients with risk factors but no known coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute treatment of migraine in adults\", section on 'Triptans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    6 mg should be limited to no more than two doses in 24 hours, and intranasal triptans to no more than three doses in 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    appears to be effective and well tolerated in the treatment of acute cluster headaches. Octreotide is a somatostatin analog with a half-life of about 90 minutes, which is much longer than the half-life of native somatostatin. In a randomized controlled trial of 91 patients, a single dose of subcutaneous octreotide (100 mcg) was superior to placebo in cluster headache response at 30 minutes (52 versus 36 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/28\">",
"     28",
"    </a>",
"    ]. Octreotide was also more effective than placebo for pain-free rates, treatment of associated symptoms, and meaningful relief. Minor gastrointestinal upset was the most common side effect of octreotide treatment.",
"   </p>",
"   <p>",
"    Although there has been no direct comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    with triptans, the results of this study suggest that octreotide is inferior to both subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    6 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/20\">",
"     20",
"    </a>",
"    ] and intranasal sumatriptan 20 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/23\">",
"     23",
"    </a>",
"    ] in terms of response rate and time to initial relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small observational studies suggest that intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is effective in at least one-third of patients, although the degree of benefit is modest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (1 mL) is administered ipsilateral to the pain in a 4 to 10 percent solution [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ]. The head position should be in extension by 45 degrees and rotated towards the symptomatic side by 30 to 40 degrees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ergots",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    has been used as a treatment for cluster headache attacks since the 1940s [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/32\">",
"     32",
"    </a>",
"    ]. Based upon clinical experience, oral ergotamine may be effective if started very early in the attack [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/33\">",
"     33",
"    </a>",
"    ], but modern trials are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"     5",
"    </a>",
"    ]. Ergotamine is available as a 2 mg sublingual tablet. The initial dose is 2 mg and may be repeated every 30 minutes with a maximum dose of 6 mg daily and 10 mg a week.",
"   </p>",
"   <p>",
"    In a small clinical trial, intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (DHE) (1 mg) was no better than placebo for reducing the duration of cluster headache attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/34\">",
"     34",
"    </a>",
"    ]. However, two small retrospective studies reported that intravenous DHE in the hospital setting may be effective for cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. DHE is given as a 1 mg intravenous bolus and may be repeated at one hour, with a maximum dose of 3 mg in 24 hours. The general limit per week is 6 mg, although this dose is sometimes exceeded in inpatients receiving a repetitive intravenous DHE protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choosing acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines recommend treatment with 100 percent oxygen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subcutaneous injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    as effective first-line options for the treatment of acute cluster headache attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/33\">",
"     33",
"    </a>",
"    ]. Oxygen should be tried first if available (eg, in a hospital or emergency clinic setting) since it is without side effects. Otherwise, subcutaneous sumatriptan 6 mg can be used as initial therapy for patients with acute cluster headache and no contraindications.",
"   </p>",
"   <p>",
"    For patients who have suboptimal response to inhaled oxygen and are unable to administer or tolerate subcutaneous injections, we suggest treatment with intranasal triptans. Choices include intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    20 mg or intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"     zolmitriptan",
"    </a>",
"    (5 mg). Intranasal triptan treatment has a slower onset of action than subcutaneous injection, but has the potential advantage of permitting more frequent treatment of recurrent attacks within a 24 hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who do not respond to or tolerate triptans and oxygen, alternative choices include subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    , and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indirect evidence suggests that intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      for acute cluster headache is less effective than triptan treatment. However, it is easy to administer and generally lacks systemic side effects.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      is effective for acute cluster headache, based upon clinical experience, and has the benefit of a longer half-life than triptans, making it an alternative that can be used as a short-term preventive treatment (evening dosage) for attacks that occur only at night.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      may be effective for acute cluster headache, based upon retrospective data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive therapy should be started as soon as possible at the onset of a cluster episode. The goal is to suppress attacks over the expected duration of the cluster period. An effective preventive regimen is of utmost importance because patients typically have one to eight cluster headaches a day, and repeated use of abortive medications may result in toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rebound.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is the agent of choice for the preventive therapy of cluster headache. Other agents that may be effective include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and methysergide.",
"   </p>",
"   <p>",
"    For patients with episodic cluster headache, prophylactic medications should be tapered after the expected duration of the cluster has passed. The drugs can be restarted at the lowest effective dose if symptoms recur.",
"   </p>",
"   <p>",
"    For patients with chronic cluster headache who have a good response to preventive pharmacotherapy, we suggest a dose reduction trial of preventive medications every other month.",
"   </p>",
"   <p>",
"    When chronic cluster headache is unresponsive to medical treatments, surgical options can be considered. However, destructive procedures aimed at the sensory trigeminal nerve or autonomic pathways are generally unproven. Occipital nerve stimulation and deep brain stimulation appear promising, but are investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is the drug of choice for prophylaxis of episodic and chronic cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/3,37,38\">",
"     3,37,38",
"    </a>",
"    ]. The best evidence supporting its effectiveness comes from a randomized controlled trial involving 30 patients with cluster headache that compared verapamil (360 mg daily in three divided doses) with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/39\">",
"     39",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      significantly reduced attack frequency and analgesic consumption during the 14 days of administration compared with placebo.",
"     </li>",
"     <li>",
"      During the first week of treatment, the median number of daily attacks, the primary outcome measure, was similar for patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and placebo (1.1 versus 1.7). However, in the second week, the median number of daily attacks was significantly lower for patients treated with verapamil (0.6 versus 1.7).",
"     </li>",
"     <li>",
"      The number of responders (defined as those with a reduction in headache frequency of &gt;50 percent at two weeks) in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and placebo arms was 12 of 15 (80 percent) and none of 15, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is usually started at a dose of 240 mg daily. Both the regular and sustained release formulations are useful, but no direct comparative studies are available. Patients treated with regular release verapamil should receive the total dose in three divided doses a day, while those treated with the sustained release formulation should receive two divided doses a day.",
"   </p>",
"   <p>",
"    There is no evidence favoring one titration method over another when treating cluster headache with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    . We suggest increasing the total daily dose by 80 mg every 10 to 14 days as tolerated. Most patients respond to a total daily dose of 240 to 320 mg. However, clinical experience suggests that some patients require a total daily dose of up to 960 mg to obtain full prophylactic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/40\">",
"     40",
"    </a>",
"    ]. In an early open label trial, titration up to a total daily verapamil dose of 1200 mg was employed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, an adequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    trial for most patients entails use of a total daily dose of 480 mg to 960 mg before the medication is regarded as a failure. The benefit of verapamil is usually seen within two to three weeks.",
"   </p>",
"   <p>",
"    The use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is associated with an increased incidence of electrocardiographic abnormalities, including heart block and bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, an electrocardiogram should be obtained after each dose increment above a total daily dose of 480 mg.",
"   </p>",
"   <p>",
"    Other side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    include edema, gastrointestinal discomfort, constipation, dull headache, and gingival hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, verapamil is usually well tolerated and can be used safely in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    , glucocorticoids, and other preventive agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have not been evaluated by rigorous randomized controlled trials for the treatment of cluster headache. However, in several open-label studies and case series, approximately 70 to 80 percent of patients with cluster headache responded to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These studies used different regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 mg daily and higher, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 mg daily given in two divided doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Regimen and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data favoring one regimen of glucocorticoid administration over another. We suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 to 100 mg once a day for at least five days, and then tapering by decreasing the dose 10 mg every day. Intravenous and oral administration of glucocorticoids can be successfully combined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients do not respond to other preventive treatments and are attack-free only with glucocorticoids. Consequently, such patients require continuous glucocorticoid therapy, which is problematic due to the deleterious side effects of prolonged systemic glucocorticoid use. These commonly include weight gain, Cushingoid facies, easy bruising and skin fragility, cataracts, aseptic necrosis of the femoral or humeral heads, hypertension, diabetes, infection, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (lithium carbonate) has not been evaluated by rigorous randomized controlled trials for the treatment of cluster headache. Evidence of effectiveness is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind controlled trial, substantial improvement in episodic cluster headache at one week occurred more often with slow-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate (800 mg daily) than with placebo (8 of 13 patients [62 percent] versus 6 of 14 [43 percent]), but the difference was statistically nonsignificant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/47\">",
"       47",
"      </a>",
"      ]. A number of methodologic issues limit the strength of this study, including small patient numbers, very short-term outcome assessment at one week, and early study termination.",
"     </li>",
"     <li>",
"      As noted earlier, a comparative, double-blind crossover trial found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      showed similar effectiveness for cluster headache prevention [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/48\">",
"       48",
"      </a>",
"      ]. However, verapamil was associated with more rapid improvement and better tolerability.",
"     </li>",
"     <li>",
"      In a review of older open label studies, the response rate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      (600 to 1500 mg daily) was as high as 78 percent overall for cluster headache, and 63 percent for episodic cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    has a narrow therapeutic window, it is generally used for patients with chronic cluster headache only when other drugs are ineffective or contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Dosing and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    should be 20",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    usually 300 mg two or three times daily, with dose increases every four to five days based upon levels; the typical maintenance dose is 900 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in three to four divided doses of the regular formulation, or in two divided doses of the sustained release formulation. The lithium plasma level should be monitored and kept between 0.6 and 1.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are hyperthyroidism, tremor, and renal dysfunction. Regular monitoring of serum lithium concentration, as well as liver, renal, and thyroid function, is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Methysergide",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled trials evaluating methysergide for cluster headache. In a review of open-label studies, the proportion of patients with a positive response to methysergide (4 to 16 mg daily) ranged from 20 to 73 percent, and it was more effective in episodic cluster headache than in chronic cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/51\">",
"     51",
"    </a>",
"    ]. Loss of effectiveness with repeated use of methysergide has been observed in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methysergide is usually started at 1 mg daily. The dose is gradually increased as tolerated to benefit, which for most responders is in the range of 4 to 12 mg daily, given in divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methysergide is metabolized to an active metabolite, methylergometrine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/52\">",
"     52",
"    </a>",
"    ]. Consequently, other",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    derivatives and triptans should be used with caution in patients who are receiving methysergide.",
"   </p>",
"   <p>",
"    Short-term side effects of methysergide include nausea, muscle cramps, abdominal pain, and pedal edema. Since there is a high incidence of pulmonary and retroperitoneal fibrosis with long-term use, the continuous use of methysergide is limited to six months.",
"   </p>",
"   <p>",
"    Methysergide is not currently marketed in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the author's clinical experience,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    is an effective add-on medication for cluster headache prevention, most often in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    . This strategy can sometimes be used to avoid the need for high-dose verapamil monotherapy or long-term glucocorticoid treatment. However, data from available open-label studies are limited and conflicting regarding the effectiveness of topiramate for the prophylaxis of cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    is 25",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    It is titrated at weekly intervals in 25 mg increments according to clinical response and tolerance, up to the recommended total daily dose of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in two divided doses. The main side effects are cognitive disturbances, paresthesia, and weight loss. It is contraindicated in nephrolithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following medications may have some usefulness as alternative options for patients with medically refractory cluster headache:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/15/40181?source=see_link\">",
"       Pizotifen",
"      </a>",
"      &ndash; The antiserotonergic drug pizotifen (3 mg daily) was effective in cluster headache prophylaxis in a single-blind, placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/56\">",
"       56",
"      </a>",
"      ]. However, a review of seven small studies suggested that pizotifen has only a modest effect [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/57\">",
"       57",
"      </a>",
"      ]. Its use is further limited by side effects such as tiredness and weight gain.",
"     </li>",
"     <li>",
"      Valproic acid &ndash; Evidence regarding the utility of valproic acid in cluster headache prophylaxis is limited and conflicting. Open-label and retrospective studies suggested benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. In contrast, a two-week double-blind randomized controlled trial involving 96 patients with cluster headache found no statistically significant difference between treatment with valproate (1000 to 2000 mg daily) and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/60\">",
"       60",
"      </a>",
"      ]. Valproic acid can be used in a dose between 5 and 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       Capsaicin",
"      </a>",
"      &ndash; Repeated ipsilateral intranasal application of capsaicin was reported to be effective in approximately two-thirds of patients with cluster headache in two open-label studies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/61,62\">",
"       61,62",
"      </a>",
"      ] and one double-blind, placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/63\">",
"       63",
"      </a>",
"      ]. Since capsaicin can induce pain, sneezing, and nasal secretions upon mucosal application, it is uncertain whether most patients were truly blind to treatment assignment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       Ergotamine",
"      </a>",
"      &ndash; Some experts advocate the combination drug caffeine (250 mg) and ergotamine (2 mg) given as a rectal suppository to prevent cluster headache attacks during the night [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/2\">",
"       2",
"      </a>",
"      ]. Ergotamine alone is not available as a suppository.",
"     </li>",
"     <li>",
"      Melatonin &ndash; Oral melatonin (10 mg) was more effective than placebo in a double-blind, randomized controlled study involving 20 patients, but the response rate was relatively low (5 of 10 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/64\">",
"       64",
"      </a>",
"      ]. In contrast, a crossover study involving nine patients with refractory cluster headache found that adjunctive melatonin did not produce any benefit compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       Indomethacin",
"      </a>",
"      &ndash; Although short-term indomethacin treatment is considered ineffective for cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/66\">",
"       66",
"      </a>",
"      ], there are reports of occasional patients meeting diagnostic criteria for cluster headache who have responded to indomethacin when used for several weeks at higher doses (&ge;225 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Triptans &ndash; A multicenter placebo-controlled trial of 169 patients found that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      was",
"      <strong>",
"       not",
"      </strong>",
"      effective in preventing cluster headache attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/68\">",
"       68",
"      </a>",
"      ]. However, limited data from small uncontrolled studies and case reports suggest that treatment with two longer-acting triptans &ndash; oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"       naratriptan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/69-71\">",
"       69-71",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"       frovatriptan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/72\">",
"       72",
"      </a>",
"      ] &ndash; is beneficial for cluster headache prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available data suggest no utility for the following agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botulinum toxin &ndash; There is no good evidence that botulinum toxin injections have any prophylactic benefit in the treatment of cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperbaric oxygen &ndash; A small placebo-controlled, double-blind trial found that hyperbaric oxygen was ineffective in preventing cluster headache attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combining preventive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no high quality evidence supporting the utility of combining various prophylactic drug treatments in cluster headache, clinical experience suggests that some patients do better with a combination of preventive medications rather than high dose monotherapy. In most instances of combined therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is given in moderate doses (240 to 480 mg daily) in conjunction with another prophylactic medication, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , or methysergide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgical methods targeting the trigeminal nerve or autonomic pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, a number of destructive surgical procedures have been used to treat chronic cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedures aimed at the sensory trigeminal nerve have targeted the trigeminal ganglion, gasserian ganglion, supraorbital nerve, infraorbital nerve, and trigeminal root. Newer procedures have targeted the occipital nerves.",
"     </li>",
"     <li>",
"      Procedures directed at autonomic pathways have targeted the greater superficial petrosal nerve, nervus intermedius, and sphenopalatine ganglion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical methods included radiofrequency thermocoagulation, glycerol gangliorhizolysis, alcohol injection, cocaine injection, gamma knife radiosurgery, and nerve sectioning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/76\">",
"     76",
"    </a>",
"    ]. However, these treatments should be considered only with great caution because reliable long-term observational data are scarce and because complications have included trigeminal neuralgia, anesthesia dolorosa, hypesthesia, meningitis, and cerebrospinal fluid leak [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available evidence, while conflicting, illustrates that trigeminal denervation may not be effective in preventing the headache attacks or autonomic symptoms of chronic cluster headache.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 10 patients utilizing gamma knife treatment, outcomes graded as excellent, good, or failure were observed in three, three, and four patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a retrospective case series of 17 patients with intractable chronic cluster headache treated with total or partial section of the trigeminal nerve root, complete or near-complete relief of symptoms at a mean follow-up of nearly seven years was reported in 15 patients (88 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case report, complete surgical section of the trigeminal sensory root had no long-term effect on the frequency or intensity of cluster attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1970607\">",
"    <span class=\"h2\">",
"     Occipital nerve procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, greater occipital nerve blockade or local glucocorticoid injection are effective, at least temporarily, for patients with refractory chronic cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. In addition, several studies found that bilateral or unilateral occipital nerve stimulation may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. In one report, 14 patients with medically intractable chronic cluster headache were treated with bilateral occipital nerve stimulation. At a median follow-up of 17.5 months, improvement was reported by 10 of 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Deep brain stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep brain stimulation (DBS) of the posterior inferior hypothalamus is a promising but unproven investigational treatment for intractable cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/90-97\">",
"     90-97",
"    </a>",
"    ]. Only small numbers of patients have been studied. The following reports illustrate the range of results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial of 11 patients with intractable chronic cluster headache, there was no significant difference at one month in the weekly frequency of attacks (the primary outcome measure) between active and sham deep brain stimulation of the posterior hypothalamus [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/97\">",
"       97",
"      </a>",
"      ]. Furthermore, there was no difference in any of the secondary outcomes between active and sham stimulation. However, at the end of a 10 month uncontrolled open phase in which all participants received chronic stimulation, the weekly frequency of attacks decreased by &ge;50 percent in 6 of 11 patients.",
"     </li>",
"     <li>",
"      In the largest series, 16 patients with chronic cluster headache refractory to drug treatment were treated with continuous hypothalamic DBS [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/93\">",
"       93",
"      </a>",
"      ]. At a mean follow-up of 23 months, a pain-free or almost pain-free outcome was noted in 13 patients (81 percent), and improved outcome was noted for the remaining three (19 percent). The mean time from DBS implantation to a stable benefit, either pain-free or pain reduction, was 42 days (range 1 to 86 days). No persistent side effects of DBS were reported.",
"     </li>",
"     <li>",
"      In smaller studies of DBS for intractable cluster headache, improvement was reported in two of four patients at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/95\">",
"       95",
"      </a>",
"      ], and in three of six patients at a mean follow-up of 17 months [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of six patients with refractory cluster headache and a mean follow-up of 15 months after DBS implantation, one patient died after developing an intracerebral hemorrhage during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/92\">",
"       92",
"      </a>",
"      ]. Another patient developed a panic attack and the procedure was aborted. In the remaining four patients, the outcome was reported as pain-free in two patients, improved in one patient, and unsatisfactory in one patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the investigational status of deep brain stimulation (DBS) and the potential for life-threatening complications, stringent criteria for patient selection have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/91\">",
"     91",
"    </a>",
"    ]. These require strictly unilateral chronic cluster headache that has been diagnosed according to International Headache Society criteria and has been present for at least 24 months; attacks must be occurring on daily basis and be refractory to all state of the art drugs alone and in combination. In addition, patients must give up smoking and drinking alcohol, have a normal, stable psychological profile, have no contraindications to DBS, have a normal neurologic examination except for symptoms characteristic of cluster (eg, persistent Horner syndrome), and have normal neuroimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Choosing preventative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    as the first option for cluster headache prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/51/3898/abstract/33\">",
"     33",
"    </a>",
"    ]. We recommend verapamil as initial therapy for patients with chronic cluster headache and for patients with relatively long-lasting active periods of episodic cluster headache. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Verapamil'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Due to the relatively long time needed to titrate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    to an effective dose, glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (DHE) may be used as adjunctive therapy in the first two weeks of verapamil administration. Glucocorticoids in particular can rapidly suppress cluster attacks during the time required for the longer-acting preventive agents to take effect.",
"   </p>",
"   <p>",
"    We suggest glucocorticoids as initial preventive therapy for patients with episodic cluster headache who have relatively short-lasting (ie, less than three weeks duration) active cluster periods. Because of their potential for systemic side effects, glucocorticoids should only be used for short-term prophylaxis. For patients who do not respond to or tolerate glucocorticoids, alternatives include methysergide (where available),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and valproic acid. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As noted in the discussion of acute treatment, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    has a relatively long half-life compared with triptans, and can be used as preventive treatment (evening dosage) for attacks that occur only at night. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ergots'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As a general rule, different preventive agents can be used in combination for patients with intolerance or contraindications to standard medications. In most instances of combined therapy, a moderate dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , or methysergide. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Combining preventive medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical treatment options can be discussed with patients who have strictly unilateral chronic cluster headache that is refractory to all available pharmacologic preventive medications. In such cases, it is particularly important to exclude potential causes of secondary cluster headache. Nevertheless, destructive surgical procedures are unproven and should be viewed with great caution. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical methods targeting the trigeminal nerve or autonomic pathways'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Occipital nerve stimulation and hypothalamic deep brain stimulation appear promising but remain investigational. (See",
"    <a class=\"local\" href=\"#H1970607\">",
"     'Occipital nerve procedures'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Deep brain stimulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster headache is one of the most severe pain syndromes known to man and can have severe functional consequences even when appropriately treated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Morbidity and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute cluster headache, we recommend initial treatment with either triptans or oxygen&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Oxygen should be tried first if available since it is without side effects. Otherwise, subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      6 mg can be used as initial therapy for patients with no contraindications. For patients who have a suboptimal response to inhaled oxygen and are unable to administer or tolerate subcutaneous injections, alternatives include intranasal sumatriptan or intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/40/2694?source=see_link\">",
"       zolmitriptan",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Triptans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute cluster headache who do not respond to or tolerate oxygen and triptans, alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      , intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Octreotide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Lidocaine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Ergots'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive therapy should be started as soon as possible at the onset of a cluster episode, with the goal of suppressing attacks over the expected duration of the cluster period. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preventive treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with chronic cluster headache and those with relatively long-lasting (ie, two months or longer) active periods of episodic cluster headache, we recommend initial preventive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The onset of benefit is dose dependent. The starting dose is usually 240 mg daily in three divided doses. Most patients respond to a total dose of 240 to 320 mg daily. Titration to a total dose of up to 960 mg daily may be necessary for some patients to obtain full prophylactic benefit. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Verapamil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with episodic cluster headache who have active cluster periods that last less than two months, we suggest initial preventive therapy with glucocorticoids alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      60 to 100 mg once a day for at least five days, followed by a taper with a dose reduction of 10 mg daily. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Destructive surgical procedures aimed at the sensory trigeminal nerve or autonomic pathways are unproven for cluster headache prophylaxis and should be viewed with great caution. Occipital nerve stimulation and hypothalamic deep brain stimulation appear promising but remain investigational. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Surgical methods targeting the trigeminal nerve or autonomic pathways'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1970607\">",
"       'Occipital nerve procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Deep brain stimulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/2\">",
"      Dodick DW, Rozen TD, Goadsby PJ, Silberstein SD. Cluster headache. Cephalalgia 2000; 20:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/3\">",
"      May A. Headaches with (ipsilateral) autonomic symptoms. J Neurol 2003; 250:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/4\">",
"      Nilsson Remahl AI, Laudon Meyer E, Cordonnier C, Goadsby PJ. Placebo response in cluster headache trials: a review. Cephalalgia 2003; 23:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/5\">",
"      May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/6\">",
"      Geweke LO. Misdiagnosis of cluster headache. Curr Pain Headache Rep 2002; 6:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/7\">",
"      Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/8\">",
"      D'Amico D, Rigamonti A, Solari A, et al. Health-related quality of life in patients with cluster headache during active periods. Cephalalgia 2002; 22:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/9\">",
"      Donnet A, Lanteri-Minet M, Guegan-Massardier E, et al. Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry 2007; 78:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/10\">",
"      Manzoni GC, Terzano MG, Moretti G, Cocchi M. Clinical observations on 76 cluster headache cases. Eur Neurol 1981; 20:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/11\">",
"      Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010; 75:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/12\">",
"      Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA 2009; 302:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/13\">",
"      Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/14\">",
"      Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation. Arch Neurol 1985; 42:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/15\">",
"      Bennett MH, French C, Schnabel A, et al. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev 2008; :CD005219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/16\">",
"      Ekbom K. Treatment of cluster headache: clinical trials, design and results. Cephalalgia 1995; 15 Suppl 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/17\">",
"      Rozen TD. High oxygen flow rates for cluster headache. Neurology 2004; 63:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/18\">",
"      Di Sabato F, Fusco BM, Pelaia P, Giacovazzo M. Hyperbaric oxygen therapy in cluster headache. Pain 1993; 52:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/19\">",
"      Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2010; :CD008042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/20\">",
"      Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. N Engl J Med 1991; 325:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/21\">",
"      Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993; 88:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/22\">",
"      Ekbom K, Krabbe A, Micieli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. Cephalalgia 1995; 15:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/23\">",
"      van Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003; 60:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/24\">",
"      Cittadini E, May A, Straube A, et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 2006; 63:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/25\">",
"      Rapoport AM, Mathew NT, Silberstein SD, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology 2007; 69:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/26\">",
"      Bahra A, Gawel MJ, Hardebo JE, et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000; 54:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/27\">",
"      Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/28\">",
"      Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. Ann Neurol 2004; 56:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/29\">",
"      Robbins L. Intranasal lidocaine for cluster headache. Headache 1995; 35:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/30\">",
"      Mills TM, Scoggin JA. Intranasal lidocaine for migraine and cluster headaches. Ann Pharmacother 1997; 31:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/31\">",
"      Markley HG. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep 2003; 7:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/32\">",
"      Ekbom, K. Ergotamine tartrate orally in Horton's histaminic cephalalgia (also called Harris's ciliary neuralgia). Acta Psychiatr Scand 1947; 46:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/33\">",
"      May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/34\">",
"      Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. Cephalalgia 1986; 6:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/35\">",
"      Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache 1991; 31:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/36\">",
"      Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011; 77:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/37\">",
"      Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache 1989; 29:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/38\">",
"      Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/39\">",
"      Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 2000; 54:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/40\">",
"      Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Curr Opin Neurol 2008; 21:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/41\">",
"      Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 2007; 69:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/42\">",
"      Noll G, L&uuml;scher TF. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology 1998; 89 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/43\">",
"      Matharu MS, van Vliet JA, Ferrari MD, Goadsby PJ. Verapamil induced gingival enlargement in cluster headache. J Neurol Neurosurg Psychiatry 2005; 76:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/44\">",
"      Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs 2002; 62:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/45\">",
"      Dodick DW, Capobianco DJ. Treatment and management of cluster headache. Curr Pain Headache Rep 2001; 5:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/46\">",
"      Mir P, Alberca R, Navarro A, et al. Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone. Neurol Sci 2003; 24:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/47\">",
"      Steiner TJ, Hering R, Couturier EG, et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997; 17:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/48\">",
"      Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache 1990; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/49\">",
"      Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981; 21:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/50\">",
"      Manzoni GC, Bono G, Lanfranchi M, et al. Lithium carbonate in cluster headache: assessment of its short- and long-term therapeutic efficacy. Cephalalgia 1983; 3:109.",
"     </a>",
"    </li>",
"    <li>",
"     Olesen, J, Tfelt-Hansen, P, Welch, K. The Headaches, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/52\">",
"      Bredberg U, Eyjolfsdottir GS, Paalzow L, et al. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 1986; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/53\">",
"      Wheeler SD, Carrazana EJ. Topiramate-treated cluster headache. Neurology 1999; 53:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/54\">",
"      F&ouml;rderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2002; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/55\">",
"      Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003; 23:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/56\">",
"      Ekbom K. Prophylactic treatment of cluster headache with a new serotonin antagonist, BC 105. Acta Neurol Scand 1969; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/57\">",
"      Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1972; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/58\">",
"      Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/59\">",
"      Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002; 102:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/60\">",
"      El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 2002; 22:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/61\">",
"      Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain 1989; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/62\">",
"      Fusco BM, Marabini S, Maggi CA, et al. Preventative effect of repeated nasal applications of capsaicin in cluster headache. Pain 1994; 59:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/63\">",
"      Marks DR, Rapoport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993; 13:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/64\">",
"      Leone M, D'Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/65\">",
"      Pringsheim T, Magnoux E, Dobson CF, et al. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache 2002; 42:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/66\">",
"      Antonaci F, Costa A, Ghirmai S, et al. Parenteral indomethacin (the INDOTEST) in cluster headache. Cephalalgia 2003; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/67\">",
"      Prakash S, Shah ND, Chavda BV. Cluster headache responsive to indomethacin: Case reports and a critical review of the literature. Cephalalgia 2010; 30:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/68\">",
"      Monstad I, Krabbe A, Micieli G, et al. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995; 35:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/69\">",
"      Eekers PJ, Koehler PJ. Naratriptan prophylactic treatment in cluster headache. Cephalalgia 2001; 21:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/70\">",
"      Loder E. Naratriptan in the prophylaxis of cluster headache. Headache 2002; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/71\">",
"      Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. Cephalalgia 2002; 22:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/72\">",
"      Siow HC, Pozo-Rosich P, Silberstein SD. Frovatriptan for the treatment of cluster headaches. Cephalalgia 2004; 24:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/73\">",
"      Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia 2002; 22:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/74\">",
"      Nilsson Remahl AI, Ansj&ouml;n R, Lind F, Waldenlind E. Hyperbaric oxygen treatment of active cluster headache: a double-blind placebo-controlled cross-over study. Cephalalgia 2002; 22:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/75\">",
"      Meyer JS, Binns PM, Ericsson AD, Vulpe M. Sphenopalatine gangionectomy for cluster headache. Arch Otolaryngol 1970; 92:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/76\">",
"      Rowed DW. Chronic cluster headache managed by nervus intermedius section. Headache 1990; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/77\">",
"      Rozen TD. Interventional treatment for cluster headache: a review of the options. Curr Pain Headache Rep 2002; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/78\">",
"      Jarrar RG, Black DF, Dodick DW, Davis DH. Outcome of trigeminal nerve section in the treatment of chronic cluster headache. Neurology 2003; 60:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/79\">",
"      Donnet A, Valade D, R&eacute;gis J. Gamma knife treatment for refractory cluster headache: prospective open trial. J Neurol Neurosurg Psychiatry 2005; 76:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/80\">",
"      Matharu MS, Goadsby PJ. Persistence of attacks of cluster headache after trigeminal nerve root section. Brain 2002; 125:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/81\">",
"      Peres MF, Stiles MA, Siow HC, et al. Greater occipital nerve blockade for cluster headache. Cephalalgia 2002; 22:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/82\">",
"      Matharu M, Khan U, McCulloch S, Shanahan P. POH05 Efficacy and safety of greater occipital nerve blocks in cluster headache. J Neurol Neurosurg Psychiatry 2010; 81:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/83\">",
"      Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/84\">",
"      Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain 2005; 118:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/85\">",
"      Gantenbein AR, Lutz NJ, Riederer F, S&aacute;ndor PS. Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache. Cephalalgia 2012; 32:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/86\">",
"      Burns B, Watkins L, Goadsby PJ. Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet 2007; 369:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/87\">",
"      Magis D, Allena M, Bolla M, et al. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 2007; 6:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/88\">",
"      Burns B, Watkins L, Goadsby PJ. Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. Neurology 2009; 72:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/89\">",
"      Magis D, Gerardy PY, Remacle JM, Schoenen J. Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache. Headache 2011; 51:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/90\">",
"      Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 2001; 345:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/91\">",
"      Leone M, May A, Franzini A, et al. Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection. Cephalalgia 2004; 24:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/92\">",
"      Schoenen J, Di Clemente L, Vandenheede M, et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 2005; 128:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/93\">",
"      Leone M, Franzini A, Broggi G, Bussone G. Hypothalamic stimulation for intractable cluster headache: long-term experience. Neurology 2006; 67:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/94\">",
"      Owen SL, Green AL, Davies P, et al. Connectivity of an effective hypothalamic surgical target for cluster headache. J Clin Neurosci 2007; 14:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/95\">",
"      Starr PA, Barbaro NM, Raskin NH, Ostrem JL. Chronic stimulation of the posterior hypothalamic region for cluster headache: technique and 1-year results in four patients. J Neurosurg 2007; 106:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/96\">",
"      Bartsch T, Pinsker MO, Rasche D, et al. Hypothalamic deep brain stimulation for cluster headache: experience from a new multicase series. Cephalalgia 2008; 28:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/51/3898/abstract/97\">",
"      Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain 2010; 11:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3351 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3898=[""].join("\n");
var outline_f3_51_3898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MORBIDITY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Triptans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Limitations to use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Octreotide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ergots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choosing acute therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Regimen and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lithium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Dosing and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Methysergide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combining preventive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgical methods targeting the trigeminal nerve or autonomic pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1970607\">",
"      Occipital nerve procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Deep brain stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Choosing preventative therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_51_3899="Risk factors for macrosomia";
var content_f3_51_3899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maternal risk factors for having a macrosomic infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       High body mass index",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiparity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Advanced maternal age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postterm pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Male infant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous macrosomic infant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Excessive weight gain in pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hispanic or African-American ethnicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal birth weight over 4000 grams",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3899=[""].join("\n");
var outline_f3_51_3899=null;
var title_f3_51_3900="Fetal erythrocyte count by GA";
var content_f3_51_3900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Erythrocyte count, 10",
"    <sup>",
"     12",
"    </sup>",
"    /L",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GA",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        2.26",
"       </td>",
"       <td>",
"        2.70",
"       </td>",
"       <td>",
"        3.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        2.41",
"       </td>",
"       <td>",
"        2.85",
"       </td>",
"       <td>",
"        3.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        2.56",
"       </td>",
"       <td>",
"        3.00",
"       </td>",
"       <td>",
"        3.43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        2.71",
"       </td>",
"       <td>",
"        3.14",
"       </td>",
"       <td>",
"        3.58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        2.85",
"       </td>",
"       <td>",
"        3.29",
"       </td>",
"       <td>",
"        3.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        3.00",
"       </td>",
"       <td>",
"        3.44",
"       </td>",
"       <td>",
"        3.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        3.15",
"       </td>",
"       <td>",
"        3.59",
"       </td>",
"       <td>",
"        4.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        3.30",
"       </td>",
"       <td>",
"        3.74",
"       </td>",
"       <td>",
"        4.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        3.44",
"       </td>",
"       <td>",
"        3.88",
"       </td>",
"       <td>",
"        4.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        3.59",
"       </td>",
"       <td>",
"        4.03",
"       </td>",
"       <td>",
"        4.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        3.74",
"       </td>",
"       <td>",
"        4.18",
"       </td>",
"       <td>",
"        4.62",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3900=[""].join("\n");
var outline_f3_51_3900=null;
var title_f3_51_3901="ITP treatment response times";
var content_f3_51_3901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Time to platelet count response for different immune thrombocytopenia (ITP) treatments",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial response* (days)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peak response",
"        <sup>",
"         &bull;",
"        </sup>",
"        (days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVIG",
"       </td>",
"       <td class=\"centered\">",
"        1 to 3",
"       </td>",
"       <td class=\"centered\">",
"        2 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-D",
"       </td>",
"       <td class=\"centered\">",
"        1 to 3",
"       </td>",
"       <td class=\"centered\">",
"        3 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenectomy",
"       </td>",
"       <td class=\"centered\">",
"        1 to 56",
"       </td>",
"       <td class=\"centered\">",
"        7 to 56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexamethasone",
"       </td>",
"       <td class=\"centered\">",
"        2 to 14",
"       </td>",
"       <td class=\"centered\">",
"        4 to 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td class=\"centered\">",
"        4 to 14",
"       </td>",
"       <td class=\"centered\">",
"        7 to 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Romiplostim",
"       </td>",
"       <td class=\"centered\">",
"        5 to 14",
"       </td>",
"       <td class=\"centered\">",
"        14 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rituximab",
"       </td>",
"       <td class=\"centered\">",
"        7 to 56",
"       </td>",
"       <td class=\"centered\">",
"        14 to 180",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eltrombopag",
"       </td>",
"       <td class=\"centered\">",
"        7 to 28",
"       </td>",
"       <td class=\"centered\">",
"        14 to 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinblastine",
"       </td>",
"       <td class=\"centered\">",
"        7 to 14",
"       </td>",
"       <td class=\"centered\">",
"        7 to 42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"       <td class=\"centered\">",
"        7 to 14",
"       </td>",
"       <td class=\"centered\">",
"        7 to 42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Danazol",
"       </td>",
"       <td class=\"centered\">",
"        14 to 90",
"       </td>",
"       <td class=\"centered\">",
"        28 to 180",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td class=\"centered\">",
"        30 to 90",
"       </td>",
"       <td class=\"centered\">",
"        30 to 180",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The expected time to initial response and peak response with various ITP treatments are listed. Treatments are listed in order of approximate rapidity of the expected initial response. Peak response reflects the time after which response becomes less likely at typically used doses. These data do not address the quality of the response (ie, absolute platelet count reached or percent increase from baseline) or the likelihood of a response for any given treatment. Refer to UpToDate topic on the treatment of ITP for details of our approach to the initial and subsequent treatment of ITP and the overall efficacy of these treatments. Refer to UpToDate topic on chronic refractory ITP for our approach to the treatment of patients for whom initial treatment is ineffective.",
"    <div class=\"footnotes\">",
"     IVIG: intravenous immune globulin.",
"     <br/>",
"     * Initial response is the first time that a response could be reasonably expected.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Peak response is the time after which a response becomes less likely at typically used doses.",
"    </div>",
"    <div class=\"reference\">",
"     Updated information from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.",
"      </li>",
"     </ol>",
"     <br/>",
"     This research was originally published in Blood. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386. Copyright &copy; 2009 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3901=[""].join("\n");
var outline_f3_51_3901=null;
var title_f3_51_3902="Contents: Cardiology calculators";
var content_f3_51_3902=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cardiology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cardiology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/14/15599\">",
"           Calculator: 10 year risk of developing cardiovascular disease in men (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/19/15679\">",
"           Calculator: 10 year risk of developing cardiovascular disease in women (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1633\">",
"           Calculator: Atrial fibrillation CHADS(2) score for stroke risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44482\">",
"           Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/63/10226\">",
"           Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28497\">",
"           Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5665\">",
"           Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25570\">",
"           Calculator: Cardiac Output",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21521\">",
"           Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/39/5746\">",
"           Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C, SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28593\">",
"           Calculator: Pulmonary Vascular Resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/48/7937\">",
"           Calculator: QT Interval Correction (EKG)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/56/26497\">",
"           Calculator: Systemic Vascular Resistance",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3824F8E2F6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_51_3902=[""].join("\n");
var outline_f3_51_3902=null;
var title_f3_51_3903="Causes of downbeat nystagmus";
var content_f3_51_3903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Causes of downbeat nystagmus in 287 patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 297px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_51_3903=[""].join("\n");
var outline_f3_51_3903=null;
